Amedeo Smart

Free Medical Literature Service

 

Amedeo

Inflammatory Bowel Diseases
  Free Subscription

Articles published in
Aliment Pharmacol Ther
    November 2026
  1. DEAN R, Yazdanfar M, Zepeda J, Patel IJ, et al
    Pruritus Is Frequent and Persistent and Impacts Quality of Life Among Patients With Primary Sclerosing Cholangitis.
    Aliment Pharmacol Ther. 2026;64:1288-1297.
    >> Share

    October 2026
  2. SUBHAHARAN D, Subramanian S
    Review Article: Beyond the Therapeutic Ceiling in Inflammatory Bowel Disease-Mechanism-Based Positioning and Emerging Therapeutic Strategies.
    Aliment Pharmacol Ther. 2026 Oct 2. doi: 10.1111/apt.70978.
    >> Share

  3. PARIGI TL, Solitano V, Mekonnen HD, Yuan Y, et al
    Systematic Review: Inclusion of Patients With Difficult-to-Treat Inflammatory Bowel Disease in Randomized Controlled Trials of Advanced Therapies.
    Aliment Pharmacol Ther. 2026 Oct 1. doi: 10.1111/apt.70998.
    >> Share

    September 2026
  4. BASTON-REY I, Rodriguez-Lago I, Barreiro-de Acosta M
    Editorial: Beyond the Matrix-Upadacitinib in Real-World Refractory Crohn's Disease.
    Aliment Pharmacol Ther. 2026 Sep 26. doi: 10.1111/apt.71019.
    >> Share

  5. LEDING C, Meddis A, Holler JG, Burisch J, et al
    Pathogen-Specific Bloodstream Infections Associated With Tumour Necrosis Factor-alpha Inhibitors, Vedolizumab and Ustekinumab in Inflammatory Bowel Disease: A Danish Nationwide Case-Control Study 2010-2024.
    Aliment Pharmacol Ther. 2026 Sep 24. doi: 10.1111/apt.70999.
    >> Share

  6. YAGUE CABALLERO C, Garcia-Lopez S, Casas-Deza D
    Editorial: Treatment Sequencing in Inflammatory Bowel Disease-Does the Line Matter More Than the Mechanism? Authors' Reply.
    Aliment Pharmacol Ther. 2026 Sep 22. doi: 10.1111/apt.71006.
    >> Share

  7. TRUNIGER S, Brand S
    Editorial: Anti-Integrin alphavbeta6 Autoantibodies for Distinguishing Ulcerative Colitis From Crohn's Disease: Authors' Reply.
    Aliment Pharmacol Ther. 2026 Sep 22. doi: 10.1111/apt.71002.
    >> Share

  8. MOHTA S, Kutum R, Dhoundiyal A, Pendyala R, et al
    Development and Prospective Validation of a Machine Learning-Based Mobile Application (CROHN'S AID) for Differentiating Crohn's Disease From Intestinal Tuberculosis in Tuberculosis-Endemic Regions.
    Aliment Pharmacol Ther. 2026 Sep 21. doi: 10.1111/apt.70984.
    >> Share

  9. TOMAS S, Chaparro M, Casanova MJ
    Editorial: Treatment Sequencing in Inflammatory Bowel Disease: Does the Line Matter More Than the Mechanism?
    Aliment Pharmacol Ther. 2026 Sep 17. doi: 10.1111/apt.70983.
    >> Share

  10. BARBERIO B, D'Amico F, Laterza L, Bezzio C, et al
    Real-World Effectiveness and Safety of Upadacitinib in Patients With Crohn's Disease-A Multicentre Prospective Study From the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD).
    Aliment Pharmacol Ther. 2026 Sep 10. doi: 10.1111/apt.70970.
    >> Share

  11. ETCHEGARAY A, Radford-Smith G, Walker G, Croft A, et al
    Letter: Acute Severe Ulcerative Colitis in the Advanced Therapy Era: Is Lowering the CRP Threshold Enough? Authors' Reply.
    Aliment Pharmacol Ther. 2026 Sep 6. doi: 10.1111/apt.70962.
    >> Share

  12. SATTAYALERTYANYONG O, Nugent Z, Bernstein CN
    Letter: Clarifying the Interpretation of Dialysis Risk in Inflammatory Bowel Disease. Authors' Reply.
    Aliment Pharmacol Ther. 2026 Sep 5. doi: 10.1111/apt.70957.
    >> Share

  13. SELINGER CP
    Editorial: How Can We Best Detect Frailty in Older Patients With Inflammatory Bowel Disease?
    Aliment Pharmacol Ther. 2026 Sep 2. doi: 10.1111/apt.70960.
    >> Share

  14. HE R, Huang Y, Han J, Zhao P, et al
    Intestinal Ultrasound Predicts Primary Non-Response and Maintenance Relapse in Upadacitinib-Treated Active Crohn's Disease: A Multicenter, Prospective Cohort Study.
    Aliment Pharmacol Ther. 2026 Sep 1. doi: 10.1111/apt.70948.
    >> Share

    August 2026
  15. KOPPELMAN LJM, Loveikyte R, van der Meulen-de Jong AE
    Letter: External Validation of Hepcidin Thresholds for Predicting Response to Iron Therapy in Active Inflammatory Bowel Disease. Authors' Reply.
    Aliment Pharmacol Ther. 2026 Aug 26. doi: 10.1111/apt.70927.
    >> Share

  16. MURAMOTO Y, Kuwada T, Shiokawa M
    Editorial: Anti-Integrin alphavbeta6 Autoantibodies for Distinguishing Ulcerative Colitis From Crohn's Disease.
    Aliment Pharmacol Ther. 2026 Aug 23. doi: 10.1111/apt.70947.
    >> Share

  17. SAWARD G, Heerasing N
    Letter: Acute Severe Ulcerative Colitis in the Advanced Therapy Era: Is Lowering the CRP Threshold Enough?
    Aliment Pharmacol Ther. 2026 Aug 23. doi: 10.1111/apt.70943.
    >> Share

  18. TRUNIGER S, Waber D, Dutschler J, Konig M, et al
    Anti-Integrin alphavbeta6 Autoantibodies Distinguish Ulcerative Colitis From Crohn's Disease With High Diagnostic Accuracy and Outperform ANCA and ASCA Status: A Prospective Cross-Sectional Study.
    Aliment Pharmacol Ther. 2026 Aug 20. doi: 10.1111/apt.70926.
    >> Share

  19. QIU L, Tang J, Yue C
    Letter: Clarifying the Interpretation of Dialysis Risk in Inflammatory Bowel Disease.
    Aliment Pharmacol Ther. 2026 Aug 12. doi: 10.1111/apt.70908.
    >> Share

  20. YAGUE CABALLERO C, Garcia Lopez S, Royo Esteban A, Figueras Panillo L, et al
    Impact of Prior Biologic Mechanism of Action on Anti-TNF Effectiveness in Inflammatory Bowel Disease: An ENEIDA Registry Study.
    Aliment Pharmacol Ther. 2026 Aug 12. doi: 10.1111/apt.70904.
    >> Share

  21. FAROOQ F, Mehmood E
    Letter on "Inflammatory Bowel Disease Is Associated With an Increased Risk of End-Stage Renal Disease: A Population-Based Cohort Study".
    Aliment Pharmacol Ther. 2026 Aug 10. doi: 10.1111/apt.70916.
    >> Share

  22. GU X, Jia Z
    Letter: From End-Stage Renal Disease Association to Risk-Stratified Kidney Surveillance in Inflammatory Bowel Disease.
    Aliment Pharmacol Ther. 2026 Aug 9. doi: 10.1111/apt.70909.
    >> Share

  23. ETCHEGARAY A, Goetz N, Hanigan K, Phillips J, et al
    Editorial on: 'Lowering the C-Reactive Protein Threshold Improves Risk Stratification in Acute Ulcerative Colitis: A Propensity-Matched Analysis'. Authors' Reply.
    Aliment Pharmacol Ther. 2026 Aug 2. doi: 10.1111/apt.70885.
    >> Share

  24. FERREIRO-IGLESIAS R, Zabana Y, Barreiro-de Acosta M
    Editorial: Risankizumab in Refractory Crohn's Disease-From Real-World Effectiveness to Strategic Positioning and Early Monitoring. Authors' Reply.
    Aliment Pharmacol Ther. 2026 Aug 2. doi: 10.1111/apt.70898.
    >> Share

  25. VISSER EH, Voshaar MAO, van Linschoten RCA, Bodelier AGL, et al
    A Care Pathway for the Treatment of IBD Reduces Healthcare Costs and Is Cost-Effective: Results of the Multicentre IBD Value Study.
    Aliment Pharmacol Ther. 2026;64:313-325.
    >> Share

    July 2026
  26. CARBALLO-FOLGOSO L, Alcorta JMD, Varela P, de Francisco R, et al
    The Prevalence of Frailty in Elderly Inflammatory Bowel Disease Patients Varies Depending on the Scale Used.
    Aliment Pharmacol Ther. 2026 Jul 31. doi: 10.1111/apt.70895.
    >> Share

  27. SALMAN Z
    Letter: External Validation of Hepcidin Thresholds for Predicting Response to Iron Therapy in Active Inflammatory Bowel Disease.
    Aliment Pharmacol Ther. 2026 Jul 27. doi: 10.1111/apt.70887.
    >> Share

  28. ETCHEGARAY A, Goetz N, Hanigan K, Phillips J, et al
    Lowering the C-Reactive Protein (CRP) Threshold Improves Risk Stratification in Acute Ulcerative Colitis: A Propensity-Matched Analysis.
    Aliment Pharmacol Ther. 2026 Jul 18. doi: 10.1111/apt.70825.
    >> Share

  29. BRADBURY M, Tyrrell-Price J
    Editorial on 'Lowering the C-Reactive Protein (CRP) Threshold Improves Risk Stratification in Acute Ulcerative Colitis: A Propensity-Matched Analysis'.
    Aliment Pharmacol Ther. 2026 Jul 18. doi: 10.1111/apt.70849.
    >> Share

  30. RICHARD N, Fumery M
    Letter: Upadacitinib in Perianal Crohn's Disease: Does Clinical Closure Reflect True Remission? Authors' Reply.
    Aliment Pharmacol Ther. 2026 Jul 15. doi: 10.1111/apt.70847.
    >> Share

  31. MARTINEZ AS, Mercader PM, Cuquerella JT, Watts MMB, et al
    Impact of Inflammatory Activity on Anorectal Function in Patients With Ulcerative Colitis: A Prospective Study.
    Aliment Pharmacol Ther. 2026 Jul 15. doi: 10.1111/apt.70855.
    >> Share

  32. SATTAYALERTYANYONG O, Nugent Z, Barr B, Bernstein KN, et al
    Inflammatory Bowel Disease Is Associated With an Increased Risk of End-Stage Renal Disease: A Population-Based Cohort Study.
    Aliment Pharmacol Ther. 2026 Jul 14. doi: 10.1111/apt.70845.
    >> Share


  33. Correction to 'Clinical Trial: Predicting Response to Iron Therapy in Patients With Active Inflammatory Bowel Disease Using Hepcidin and Functional Iron Indices: A Multicentre Randomised Trial'.
    Aliment Pharmacol Ther. 2026 Jul 14. doi: 10.1111/apt.70861.
    >> Share

  34. ERNEST-SUAREZ K, Hoentjen F
    Editorial: Risankizumab in Refractory Crohn's Disease-From Real-World Effectiveness to Strategic Positioning and Early Monitoring.
    Aliment Pharmacol Ther. 2026 Jul 13. doi: 10.1111/apt.70858.
    >> Share

  35. BATRA G, Shukla A, Chatterjee A, Chandnani S, et al
    Meta-Analysis: Crohn's Disease Exclusion Diet for Induction and Maintenance in Crohn's Disease.
    Aliment Pharmacol Ther. 2026 Jul 12. doi: 10.1111/apt.70857.
    >> Share

  36. YOUNG D, Booker C, Samaan M, Kok K, et al
    Real-World Effectiveness, Safety and Quality of Life With Ustekinumab for the Treatment of Crohn's Disease: Results of the UK Ustekinumab Real World Evidence Study (UndieS) Study Group.
    Aliment Pharmacol Ther. 2026 Jul 9. doi: 10.1111/apt.70833.
    >> Share

  37. ZHU A, Segal JP
    Letter: Nuanced Interpretation of Faecal Calprotectin During Maintenance of Ulcerative Colitis Treatment: Sweet Spots and Pitfalls.
    Aliment Pharmacol Ther. 2026 Jul 9. doi: 10.1111/apt.70839.
    >> Share

  38. ELDESOUKI MH, Ibrahim A, Marey MM, Francis FF, et al
    Risk of Myeloproliferative Neoplasms in Patients With Inflammatory Bowel Disease and Impact on Outcomes: A Multi-Centre Matched Analysis.
    Aliment Pharmacol Ther. 2026 Jul 3. doi: 10.1111/apt.70779.
    >> Share

  39. COLLINS K, Kamath S, Davis RH, Costello SP, et al
    Review Article: The Impact of the Gut Microbiome on Ulcerative Colitis Pharmacotherapy.
    Aliment Pharmacol Ther. 2026 Jul 1. doi: 10.1111/apt.70826.
    >> Share

    June 2026
  40. TANG CZ, Faye AS
    Letter: Does the Association Between Mild Endoscopic Activity and Adverse Outcomes Justify Treatment Escalation in Older Adults With Inflammatory Bowel Disease? Authors' Reply.
    Aliment Pharmacol Ther. 2026 Jun 22. doi: 10.1111/apt.70822.
    >> Share

  41. RICHARD N, Fumery M
    Editorial: Upadacitinib in Perianal Crohn's Disease. Authors' Reply.
    Aliment Pharmacol Ther. 2026 Jun 20. doi: 10.1111/apt.70817.
    >> Share

  42. QIU L, Tang J, Yue C
    Letter: Does the Association Between Mild Endoscopic Activity and Adverse Outcomes Justify Treatment Escalation in Older Adults With Inflammatory Bowel Disease?
    Aliment Pharmacol Ther. 2026 Jun 19. doi: 10.1111/apt.70804.
    >> Share

  43. SAWARD G, Heerasing N
    Letter: Upadacitinib in Perianal Crohn's Disease: Does Clinical Closure Reflect True Remission?
    Aliment Pharmacol Ther. 2026 Jun 18. doi: 10.1111/apt.70815.
    >> Share

  44. BOKEMEYER A, Tran F, Plachta-Danielzik S, Gilman E, et al
    Comparative Real-World Effectiveness of Anti-TNF, Ustekinumab and Vedolizumab in Crohn's Disease Over 24 Months: A Pooled Analysis From the Prospective UMBRELLA-IBD Registry in Germany.
    Aliment Pharmacol Ther. 2026 Jun 15. doi: 10.1111/apt.70796.
    >> Share

  45. VISSER EH, Voshaar MAO, van Linschoten RCA, Bodelier AGL, et al
    Editorial: Inflammatory Bowel Disease Care Pathways-Improving Quality, but Not at Increased Cost. Authors' Reply.
    Aliment Pharmacol Ther. 2026 Jun 10. doi: 10.1111/apt.70780.
    >> Share

  46. BARREIRO-DE ACOSTA M, Zabana Y, Nieto-Garcia L, Poncela M, et al
    Real-World Effectiveness of Risankizumab in Refractory Crohn's Disease: The RISANCROHN Study From the ENEIDA Registry.
    Aliment Pharmacol Ther. 2026 Jun 10. doi: 10.1111/apt.70783.
    >> Share

  47. KOPPELMAN LJM, Loveikyte R, Goetgebuer RL, van der Marel S, et al
    Clinical Trial: Predicting Response to Iron Therapy in Patients With Active Inflammatory Bowel Disease Using Hepcidin and Functional Iron Indices: A Multicentre Randomised Trial.
    Aliment Pharmacol Ther. 2026 Jun 8. doi: 10.1111/apt.70775.
    >> Share

  48. DUBE LR, Sorin M, Allez M, Afif W, et al
    The Association of Faecal Calprotectin Measurements With Endo-Histological Remission in Ulcerative Colitis: A Pooled Analysis.
    Aliment Pharmacol Ther. 2026 Jun 2. doi: 10.1111/apt.70735.
    >> Share

  49. GOYAL MK, Bishu S
    Editorial: Upadacitinib in Perianal Crohn's Disease.
    Aliment Pharmacol Ther. 2026 Jun 2. doi: 10.1111/apt.70759.
    >> Share

  50. GOYAL MK, Srivastava H, Sehgal T, Bishu S, et al
    Review Article: TL1A Inhibitors in IBD - Mechanistic Rationale and Clinical Evidence.
    Aliment Pharmacol Ther. 2026;63:1458-1473.
    >> Share

    May 2026
  51. GARCIA JLR, Suarez-Ferrer C, Zabana Y
    Letter: Early Inflammatory Benefit Is Not Yet Equivalent to Durable Surgical Advantage After Colectomy in Colonic Crohn's Disease. Authors' Reply.
    Aliment Pharmacol Ther. 2026 May 12. doi: 10.1111/apt.70715.
    >> Share

  52. BURR N
    Editorial: Inflammatory Bowel Disease Care Pathways-Improving Quality, but Not at Increased Cost.
    Aliment Pharmacol Ther. 2026 May 11. doi: 10.1111/apt.70726.
    >> Share

    April 2026
  53. GARCIA JLR, Suarez-Ferrer C, Zabana Y
    Editorial: Beyond Resection-Rethinking Postoperative Management in Colonic Crohn's Disease. Authors' Reply.
    Aliment Pharmacol Ther. 2026 Apr 27. doi: 10.1111/apt.70702.
    >> Share

  54. RICHARD N, Seksik P, Altwegg R, Nachury M, et al
    One-Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real-World GETAID Study.
    Aliment Pharmacol Ther. 2026 Apr 27. doi: 10.1111/apt.70682.
    >> Share

  55. LI J
    Letter: Early Inflammatory Benefit Is Not Yet Equivalent to Durable Surgical Advantage After Colectomy in Colonic Crohn's Disease.
    Aliment Pharmacol Ther. 2026 Apr 25. doi: 10.1111/apt.70700.
    >> Share

  56. FONS AB, Asscher VER, Mooijaart SP, Maljaars PWJ, et al
    Editorial: Optimal Treatment for Older Patients With Inflammatory Bowel Disease: How to Detect and Manage Frailty? Authors' Reply.
    Aliment Pharmacol Ther. 2026 Apr 25. doi: 10.1111/apt.70660.
    >> Share

  57. RIGGOTT C, Fairbrass KM, Guthrie EA, Black CJ, et al
    Letter: The Persistence of Anxiety and Depression in Inflammatory Bowel Disease-A Core Phenotype Beyond Inflammatory Activity. Authors' Reply.
    Aliment Pharmacol Ther. 2026 Apr 17. doi: 10.1111/apt.70673.
    >> Share

  58. BERTIN L, Savarino EV
    Letter: Beyond the Mucosa-Strengthening the Case for Transmural Healing as a Monitoring Target in Crohn's Disease.
    Aliment Pharmacol Ther. 2026 Apr 17. doi: 10.1111/apt.70674.
    >> Share

  59. MURTHY SK
    Letter: Are All Extra-Digestive Cancer Signals in Inflammatory Bowel Disease Telling the Same Story? Authors' Reply.
    Aliment Pharmacol Ther. 2026 Apr 16. doi: 10.1111/apt.70679.
    >> Share

  60. SINGH AK, Birda CL
    Letter: Optimising Hepatitis B Vaccination in Inflammatory Bowel Disease-Expanding Strategies Beyond Double-Dose Recombinant Vaccination. Authors' Reply.
    Aliment Pharmacol Ther. 2026 Apr 15. doi: 10.1111/apt.70687.
    >> Share

  61. WANG R, Cao D, Cui Z
    Editorial-Fistula Calprotectin as a Biomarker of Local Inflammation and Treatment Response in Perianal Fistulising Crohn's Disease. Authors' Reply.
    Aliment Pharmacol Ther. 2026 Apr 15. doi: 10.1111/apt.70672.
    >> Share

  62. ARATARI A, Festa S
    Editorial: Beyond Resection-Rethinking Postoperative Management in Colonic Crohn's Disease.
    Aliment Pharmacol Ther. 2026 Apr 15. doi: 10.1111/apt.70680.
    >> Share

  63. FONS AB, Maljaars PWJ
    Letter: Incremental Value and Outcome Modelling in Frailty Assessment for Older Patients with Inflammatory Bowel Disease. Author's Reply.
    Aliment Pharmacol Ther. 2026 Apr 14. doi: 10.1111/apt.70681.
    >> Share

  64. KUMAR A, Patil AN, Sharma V
    Letter: Steroid Tapering in Ulcerative Colitis-The Importance of Disease Severity and Maintenance Therapy. Authors' Reply.
    Aliment Pharmacol Ther. 2026 Apr 8. doi: 10.1111/apt.70661.
    >> Share

  65. O'CONNOR R, Karunadasa H, Vasudevan A
    Letter: Steroid Tapering in Ulcerative Colitis: The Importance of Disease Severity and Maintenance Therapy.
    Aliment Pharmacol Ther. 2026 Apr 5. doi: 10.1111/apt.70642.
    >> Share

  66. YZET C, Plancke A, Brazier F, Grados L, et al
    Intestinal Ultrasound Transmural Healing Was Associated With Improved Long-Term Outcomes Among Patients With Endoscopic Remission: Results of a Prospective Study.
    Aliment Pharmacol Ther. 2026;63:992-999.
    >> Share

    March 2026
  67. HEGDE Y, Caldera F
    Letter: Optimising Hepatitis B Vaccination in Inflammatory Bowel Disease - Expanding Strategies Beyond Double-Dose Recombinant Vaccination.
    Aliment Pharmacol Ther. 2026 Mar 31. doi: 10.1111/apt.70651.
    >> Share

  68. JIAO L, Cao Y
    Letter: Are All Extra-Digestive Cancer Signals in Inflammatory Bowel Disease Telling the Same Story?
    Aliment Pharmacol Ther. 2026 Mar 31. doi: 10.1111/apt.70650.
    >> Share

  69. BARBERIO B, Savarino EV
    Letter: The Persistence of Anxiety and Depression in Inflammatory Bowel Disease: A Core Phenotype Beyond Inflammatory Activity.
    Aliment Pharmacol Ther. 2026 Mar 31. doi: 10.1111/apt.70641.
    >> Share

  70. ALSOUDANI A, Swaminathan A
    Editorial: Fistula Calprotectin as a Biomarker of Local Inflammation and Treatment Response in Perianal Fistulising Crohn's Disease.
    Aliment Pharmacol Ther. 2026 Mar 30. doi: 10.1111/apt.70640.
    >> Share

  71. LIU C, He D, Wei A, Xu L, et al
    Letter: Incremental Value and Outcome Modelling in Frailty Assessment for Older Patients With Inflammatory Bowel Disease.
    Aliment Pharmacol Ther. 2026 Mar 19. doi: 10.1111/apt.70632.
    >> Share

  72. KUMAR A, Patil A, Sharma V
    Letter: Thiopurines the Silent Workhorse for Many Patients After a Flare of Ulcerative Colitis. Authors' Reply.
    Aliment Pharmacol Ther. 2026 Mar 19. doi: 10.1111/apt.70624.
    >> Share

  73. SALUJA H, Chinnaratha MA
    Letter: Is Short Tapering of Steroids in Moderate to Severely Active Ulcerative Colitis Really Inferior to a Long Steroid Taper, or Just Underpowered to Reach a Definitive Conclusion?
    Aliment Pharmacol Ther. 2026 Mar 18. doi: 10.1111/apt.70633.
    >> Share

  74. CARBERY I, Selinger CP
    Editorial: Optimal Treatment for Older Patients With Inflammatory Bowel Disease: How to Detect and Manage Frailty?
    Aliment Pharmacol Ther. 2026 Mar 18. doi: 10.1111/apt.70621.
    >> Share

  75. SAWARD G, Segal J
    Letter: Thiopurines the Silent Workhorse for Many Patients After a Flare of Ulcerative Colitis.
    Aliment Pharmacol Ther. 2026 Mar 18. doi: 10.1111/apt.70617.
    >> Share

  76. REJI R, Novak K
    Editorial: "Striding" Towards Transmural Healing: Redefining Deep Remission as a Treatment Target in Crohn's Disease.
    Aliment Pharmacol Ther. 2026 Mar 17. doi: 10.1111/apt.70513.
    >> Share

  77. RUEDA GARCIA JL, Suarez Ferrer C, Garcia de la Filia Molina I, Rivas C, et al
    Post-Operative Recurrence of Colonic Crohn's Disease After Colectomy: The RESECOL Study by the Young Group of GETECCU.
    Aliment Pharmacol Ther. 2026 Mar 12. doi: 10.1111/apt.70608.
    >> Share

  78. VAN WEES JC, Little RD, Melton SL
    Letter: Eating Disorders in Inflammatory Bowel Disease-Are We Asking the Right Questions?
    Aliment Pharmacol Ther. 2026 Mar 10. doi: 10.1111/apt.70582.
    >> Share

  79. FONS AB, Asscher VER, Stuyt RJL, Baven-Pronk AMC, et al
    Frailty Is Associated With All-Cause and Acute Hospitalisations During 18 Months Follow-Up in Older Patients With Inflammatory Bowel Disease.
    Aliment Pharmacol Ther. 2026 Mar 8. doi: 10.1111/apt.70594.
    >> Share

  80. WANG R, Wu Y, Xu D, Yang Y, et al
    Fistula Calprotectin as a Biomarker of Local Inflammation and Treatment Response in Perianal Fistulizing Crohn's Disease.
    Aliment Pharmacol Ther. 2026 Mar 3. doi: 10.1111/apt.70600.
    >> Share

  81. AHUJA D, Park SK, Yeh KH, Patel SB, et al
    Overall and Comparative Risk of Shingles With Advanced Therapies in Patients With Inflammatory Bowel Diseases.
    Aliment Pharmacol Ther. 2026;63:686-695.
    >> Share

  82. AHUJA D, Yeh KH, Patel SB, Park SK, et al
    Research Communication: Risk of Tuberculosis With Advanced Therapies in 20,705 Patients With Inflammatory Bowel Diseases in Low Incidence Regions-A U.S. Claims-Based Study.
    Aliment Pharmacol Ther. 2026;63:885-887.
    >> Share

  83. FAYE AS, Axelrad J, Sun J, Halfvarsson J, et al
    Treatment-Free Outcomes Following Surgery for IBD: A Nationwide Cohort Study.
    Aliment Pharmacol Ther. 2026;63:821-837.
    >> Share

    February 2026
  84. MEDAWAR E, Chaudhary H, Zoughlami A, Ekhdoura M, et al
    Systematic Review of Published Guidelines: Recommendations for Exams Under Anaesthesia, Seton Insertion and Timing of Seton Removal for Perianal and Rectovaginal Fistulising Crohn's Disease.
    Aliment Pharmacol Ther. 2026 Feb 16. doi: 10.1111/apt.70569.
    >> Share

  85. ALSAKARNEH S, Tome J, Farraye FA, Pardi DS, et al
    Research Communication: Comparative Effectiveness of Ustekinumab and Vedolizumab in the Management of Chronic Pouchitis-A Population-Based Study.
    Aliment Pharmacol Ther. 2026;63:424-428.
    >> Share

    January 2026
  86. PATIL AN, Kumar A, Sharma V
    Letter: A Patient Centric Approach to Tapering Steroids in Steroid Responsive Moderate to Severely Active Ulcerative Colitis. Authors' Reply.
    Aliment Pharmacol Ther. 2026 Jan 29. doi: 10.1111/apt.70552.
    >> Share

  87. BHAT G, Shetty A
    Letter: A Patient Centric Approach to Tapering Steroids in Steroid Responsive Moderate to Severely Active Ulcerative Colitis.
    Aliment Pharmacol Ther. 2026 Jan 28. doi: 10.1111/apt.70546.
    >> Share

  88. KUMAR A, Patil AN, Grewal J, Kumaravel J, et al
    Clinical Trial: Long Versus Short Tapering of Steroids in Steroid Responsive Moderate to Severely Active Ulcerative Colitis-A Randomised Controlled Trial.
    Aliment Pharmacol Ther. 2026 Jan 2. doi: 10.1111/apt.70509.
    >> Share

  89. LU C, Verstockt B, Winter MW, Christensen B, et al
    Review Article: Extending the Frontiers of Intestinal Ultrasound Knowledge, Performance and Expansion.
    Aliment Pharmacol Ther. 2026;63:40-56.
    >> Share

  90. ATTAUABI M, Madsen GR, Bendtsen F, Seidelin JB, et al
    Research Communication: Sexual Dysfunction is a Common Early Challenge in Newly Diagnosed Inflammatory Bowel Disease.
    Aliment Pharmacol Ther. 2026;63:288-293.
    >> Share

    December 2025
  91. GODDARD Q, Markovinovic A, Ronksley PE, Seow C, et al
    Meta-Analysis: Prevalence of Eating Disorders in Inflammatory Bowel Disease.
    Aliment Pharmacol Ther. 2025 Dec 27. doi: 10.1111/apt.70492.
    >> Share

  92. GIRI S, Jena A, Sharma V, Sebastian S, et al
    Editorial: The Hidden Burden-Stigmatisation in Inflammatory Bowel Disease: Authors' Reply.
    Aliment Pharmacol Ther. 2025 Dec 21. doi: 10.1111/apt.70507.
    >> Share

  93. LENTI MV, Santacroce G, Di Sabatino A
    Editorial: The Hidden Burden-Stigmatisation in Inflammatory Bowel Disease.
    Aliment Pharmacol Ther. 2025 Dec 21. doi: 10.1111/apt.70478.
    >> Share

    November 2025
  94. MARACLE B, Quan S, Hamilton P, Shaikh A, et al
    Systematic Review: Efficacy, Safety and Metabolic Outcomes of GLP-1 Receptor Agonists in Inflammatory Bowel Disease.
    Aliment Pharmacol Ther. 2025 Nov 30. doi: 10.1111/apt.70485.
    >> Share

  95. SODERHOLM JD
    Editorial: The Appendix-A Dead End for Treating Ulcerative Colitis, After All?
    Aliment Pharmacol Ther. 2025 Nov 25. doi: 10.1111/apt.70370.
    >> Share

  96. DERKS MEW, Hoentjen F
    Editorial: High-Grade Dysplasia in Colonic Inflammatory Bowel Disease Is Associated With a High Risk of Synchronous or Metachronous Colorectal Cancer-Authors' Reply.
    Aliment Pharmacol Ther. 2025 Nov 24. doi: 10.1111/apt.70473.
    >> Share

  97. HICKEY A, Dong C, Lamb CA
    Editorial: High-Grade Dysplasia in Colonic Inflammatory Bowel Disease Is Associated With a High Risk of Synchronous or Metachronous Colorectal Cancer.
    Aliment Pharmacol Ther. 2025 Nov 24. doi: 10.1111/apt.70442.
    >> Share

  98. SINGH AK, Soni RK, Jearth V, Yadav AI, et al
    Clinical Trial: Immunogenicity of Double-Dose Versus Standard-Dose of Hepatitis B Virus Vaccine in Inflammatory Bowel Disease.
    Aliment Pharmacol Ther. 2025 Nov 20. doi: 10.1111/apt.70470.
    >> Share

  99. LEE JD, Papamichael K, Grinspan LT, Cheifetz AS, et al
    Editorial: Mitigating the Risk of Adverse Pregnancy Outcomes in Women With Inflammatory Bowel Disease and Chronic Liver Disease-Authors' Reply.
    Aliment Pharmacol Ther. 2025 Nov 17. doi: 10.1111/apt.70467.
    >> Share

  100. CHUNG Y, Nayagam JS
    Editorial: Mitigating the Risk of Adverse Pregnancy Outcomes in Women With Inflammatory Bowel Disease and Chronic Liver Disease.
    Aliment Pharmacol Ther. 2025 Nov 17. doi: 10.1111/apt.70444.
    >> Share

  101. BAILLIE S, Blackwell J, Pollok R
    Letter: From Descriptive Epidemiology to Clinical Imperative-Challenging the Paradigm of Pain and Sedative Use in Inflammatory Bowel Disease. Authors' Reply.
    Aliment Pharmacol Ther. 2025 Nov 12. doi: 10.1111/apt.70459.
    >> Share

  102. YANG D, Yang J, Wang S, Wang G, et al
    Letter: From Descriptive Epidemiology to Clinical Imperative-Challenging the Paradigm of Pain and Sedative Use in Inflammatory Bowel Disease.
    Aliment Pharmacol Ther. 2025 Nov 12. doi: 10.1111/apt.70416.
    >> Share

  103. MURTHY SK, Ahmed F, Pugliese M, Taljaard M, et al
    A Population-Based Matched Cohort Study of Extra-Digestive Cancer Incidence and Mortality in Individuals With and Without Inflammatory Bowel Disease.
    Aliment Pharmacol Ther. 2025 Nov 11. doi: 10.1111/apt.70439.
    >> Share

  104. GIRI S, Harindranath S, Chandnani S, Jena A, et al
    Systematic Review: Stigma Associated With Inflammatory Bowel Disease.
    Aliment Pharmacol Ther. 2025 Nov 4. doi: 10.1111/apt.70448.
    >> Share

  105. PATEL P, Belesiotis P, Rai NS, Yuan Y, et al
    Meta-Analysis: Improvement of Bowel Urgency With Advanced Therapies for Inflammatory Bowel Disease.
    Aliment Pharmacol Ther. 2025 Nov 4. doi: 10.1111/apt.70446.
    >> Share

    October 2025
  106. DERKS MEW, Te Groen M, Derikx LAAP, Nagtegaal ID, et al
    High Risk of Colorectal Cancer After High-Grade Dysplasia in Inflammatory Bowel Disease Patients.
    Aliment Pharmacol Ther. 2025 Oct 24. doi: 10.1111/apt.70429.
    >> Share

  107. LEE JD, Papamichael K, Grinspan LT, Cheifetz AS, et al
    Maternal and Perinatal Outcomes in Pregnant Women With Comorbid Inflammatory Bowel Disease and Chronic Liver Disease.
    Aliment Pharmacol Ther. 2025 Oct 23. doi: 10.1111/apt.70425.
    >> Share

  108. RIGGOTT C, Fairbrass KM, Guthrie EA, Black CJ, et al
    Persistence of Symptoms of Anxiety and Depression in Inflammatory Bowel Disease: A Longitudinal Follow-Up Study.
    Aliment Pharmacol Ther. 2025 Oct 21. doi: 10.1111/apt.70431.
    >> Share

  109. ROUVEYRE R, Coudol S, Collins M, de Maissin A, et al
    Clinical Trial: Simplified Bowel Preparation for Small Bowel Capsule Endoscopy in Crohn's Disease.
    Aliment Pharmacol Ther. 2025 Oct 20. doi: 10.1111/apt.70417.
    >> Share

  110. TANG CZ, Delau OR, Katz S, Axelrad JE, et al
    Mild Endoscopic Disease Activity Is Associated With Adverse Outcomes Among Older Adults With Inflammatory Bowel Disease.
    Aliment Pharmacol Ther. 2025 Oct 15. doi: 10.1111/apt.70414.
    >> Share

  111. ELFORD AT, Constantine-Cooke N, Jenkinson PW, Gros B, et al
    Twenty-Year Trends in Colectomy Rates and Advanced Therapy Prescribing in Lothian, Scotland.
    Aliment Pharmacol Ther. 2025;62:699-709.
    >> Share

    September 2025
  112. POLLOK R
    Letter: Temporal Trends in the Rate of Colectomy in Ulcerative Colitis.
    Aliment Pharmacol Ther. 2025 Sep 30. doi: 10.1111/apt.70368.
    >> Share

  113. MATHIAS RM, Bogatic D, Bryant RV
    Editorial: Is Disease Clearance the Target in Ulcerative Colitis or a Stride Too Far?
    Aliment Pharmacol Ther. 2025 Sep 26. doi: 10.1111/apt.70291.
    >> Share

  114. MASSIRONI S, Zilli A, Furfaro F, Allocca M, et al
    Systematic Review: Ultrasound Goes Echo-Decarbonising Inflammatory Bowel Disease Care Through Intestinal Ultrasound.
    Aliment Pharmacol Ther. 2025 Sep 23. doi: 10.1111/apt.70385.
    >> Share

  115. RUBIN DE CELIX C, Chaparro M, Gisbert JP
    Editorial: Managing the Moving Target-Dose Adjustments in Inflammatory Bowel Disease. Authors' Reply.
    Aliment Pharmacol Ther. 2025 Sep 17. doi: 10.1111/apt.70379.
    >> Share

  116. CLARK N, Tassone D, Ding NS
    Editorial: Managing the Moving Target-Dose Adjustments in Inflammatory Bowel Disease.
    Aliment Pharmacol Ther. 2025 Sep 17. doi: 10.1111/apt.70340.
    >> Share

  117. NATT N, Gindi M, Dela Cruz GR, Ponich T, et al
    IL23 Receptor Polymorphism Is a Predictor of Anti-Tumour Necrosis Factor-alpha-Induced Paradoxical Psoriasis in Inflammatory Bowel Disease.
    Aliment Pharmacol Ther. 2025 Sep 16. doi: 10.1111/apt.70377.
    >> Share

  118. NORDESTGAARD RLM, Lo B, Bergstrom R, Adzioski I, et al
    Clinical Trial: Evaluating a Single 1600 mg Tablet Regimen of 5-Aminosalicylate for Ulcerative Colitis-The EASI Trial.
    Aliment Pharmacol Ther. 2025 Sep 16. doi: 10.1111/apt.70375.
    >> Share

  119. LE COSQUER G, Laharie D
    Editorial: Ulcerative Colitis Management in the Biologic Era-Data From the English Healthcare Databases.
    Aliment Pharmacol Ther. 2025 Sep 11. doi: 10.1111/apt.70346.
    >> Share

  120. SINGH M, Grover M, Petrik M
    Letter: Multidisciplinary Approach for Inflammatory Bowel Disease to Promote Value-Based Care.
    Aliment Pharmacol Ther. 2025 Sep 9. doi: 10.1111/apt.70369.
    >> Share

  121. COUCH J, Thomas K, Card TR, Humes DJ, et al
    Editorial: Ulcerative Colitis Management in the Biologic Era-Data From the English Healthcare Databases. Authors' Reply.
    Aliment Pharmacol Ther. 2025 Sep 8. doi: 10.1111/apt.70362.
    >> Share

    August 2025
  122. MAHADEVAN U, Seow CH, Barnes EL, Chaparro M, et al
    Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease.
    Aliment Pharmacol Ther. 2025 Aug 28. doi: 10.1111/apt.70290.
    >> Share

  123. RANJAN MK, Vuyyuru SK
    Editorial: Corticosteroid Responsive Acute Severe Ulcerative Colitis-Revisiting Maintenance Approaches in the Era of Advanced Therapies.
    Aliment Pharmacol Ther. 2025 Aug 26. doi: 10.1111/apt.70288.
    >> Share

  124. LIN KJ, Hung CH, Wei JC
    Letter: Crohn's Disease or Comorbidity? Reassessing Opioid Prescribing Patterns.
    Aliment Pharmacol Ther. 2025 Aug 23. doi: 10.1111/apt.70311.
    >> Share

  125. OSOOLI M, Olen O
    Letter: Crohn's Disease or Comorbidity? Reassessing Opioid Prescribing Patterns. Authors' Reply.
    Aliment Pharmacol Ther. 2025 Aug 23. doi: 10.1111/apt.70356.
    >> Share

  126. BAYOUMY AB, de Boer NK
    Editorial: Dual Advanced Therapy in Refractory Ulcerative Colitis-Hope Beyond Monotherapy.
    Aliment Pharmacol Ther. 2025 Aug 15. doi: 10.1111/apt.70318.
    >> Share

  127. NEELAM PB, Banerjee R
    Editorial: Dual Advanced Therapy in Refractory Ulcerative Colitis-Hope Beyond Monotherapy. Authors' Reply.
    Aliment Pharmacol Ther. 2025 Aug 15. doi: 10.1111/apt.70339.
    >> Share

  128. COUCH J, Thomas K, Card TR, Humes DJ, et al
    Temporal Trends in Medical and Surgical Management of Ulcerative Colitis in England: 2003-2020.
    Aliment Pharmacol Ther. 2025 Aug 8. doi: 10.1111/apt.70319.
    >> Share

  129. RUBIN DE CELIX C, Ricart E, Martin-Arranz MD, de Francisco R, et al
    Frequency and Effectiveness of Dose Escalation and De-Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW-IBD Study of ENEIDA.
    Aliment Pharmacol Ther. 2025 Aug 8. doi: 10.1111/apt.70312.
    >> Share

  130. NEELAM PB, Mekala D, Patel R, Banerjee R, et al
    Efficacy and Safety of Vedolizumab and Tofacitinib (VETO) Combination Therapy in Refractory Ulcerative Colitis Unresponsive to Anti-TNF and a Second-Line Advanced Therapy: A Prospective Cohort Nested Within a Randomised Trial.
    Aliment Pharmacol Ther. 2025 Aug 4. doi: 10.1111/apt.70309.
    >> Share

  131. UZZAN M, Laharie D, Kirchgesner J
    Editorial: JAK to JAK-Navigating Intra-Class JAK Inhibitor Switching in Inflammatory Bowel Disease. Authors' Reply.
    Aliment Pharmacol Ther. 2025;62:460-461.
    >> Share

    July 2025
  132. AKIYAMA S
    Editorial: Evolving Trends in Ulcerative Colitis Management-Insights From the Lothian Cohort.
    Aliment Pharmacol Ther. 2025 Jul 30. doi: 10.1111/apt.70249.
    >> Share

  133. SHEHAB M, Alrashed F, Alrashidi A, Hassan A, et al
    Network Meta-Analysis: Comparative Efficacy of Biologics and Small Molecules in the Induction and Maintenance of Remission in Crohn's Disease.
    Aliment Pharmacol Ther. 2025 Jul 27. doi: 10.1111/apt.70295.
    >> Share

  134. ALSAKARNEH S, Aburumman R, Bilal M, Faye AS, et al
    Primary Sclerosing Cholangitis in the Absence of Inflammatory Bowel Disease Increases the Risk of Colorectal Cancer: A Multi-Centre Propensity Score Matched Analysis.
    Aliment Pharmacol Ther. 2025 Jul 24. doi: 10.1111/apt.70303.
    >> Share

  135. DALAL RS, Clarke LM, Cabral HJ, Carlin AD, et al
    Research Communication: Combination Therapy of Upadacitinib With Infliximab, Risankizumab, Ustekinumab or Vedolizumab for Refractory Crohn's Disease: A Descriptive Case Series.
    Aliment Pharmacol Ther. 2025 Jul 24. doi: 10.1111/apt.70298.
    >> Share

  136. LUNDQVIST E, Westberg K, Boman SE, Myrberg IH, et al
    Outcome After Surgery for Colon Cancer in a National Cohort of Patients With and Without Inflammatory Bowel Disease.
    Aliment Pharmacol Ther. 2025 Jul 22. doi: 10.1111/apt.70296.
    >> Share

  137. MARK-CHRISTENSEN A, Kristiansen EB, Laurberg S, Erichsen R, et al
    Appendectomy Is Not Associated With a Milder Clinical Course of Ulcerative Colitis: A Nationwide Danish Population-Based Study.
    Aliment Pharmacol Ther. 2025 Jul 21. doi: 10.1111/apt.70279.
    >> Share

  138. RIGGOTT C, Gracie DJ, Ford AC
    Editorial on 'Prevalence and Predictors of Symptoms of Anxiety or Depression at Diagnosis in Patients With Inflammatory Bowel Disease: An Inception Cohort'. Authors' Reply.
    Aliment Pharmacol Ther. 2025 Jul 18. doi: 10.1111/apt.70293.
    >> Share

  139. LORES T, Keefer L
    Editorial on 'Prevalence and Predictors of Symptoms of Anxiety or Depression at Diagnosis in Patients With Inflammatory Bowel Disease: An Inception Cohort'.
    Aliment Pharmacol Ther. 2025 Jul 18. doi: 10.1111/apt.70272.
    >> Share

  140. DANESE S, Leong RW, Sands BE, Ma T, et al
    Clinical Trial: Association Between Early Disease Clearance and Long-Term Outcomes-4-Year Results From the Phase 3 UNIFI Study of Ustekinumab in Ulcerative Colitis.
    Aliment Pharmacol Ther. 2025 Jul 16. doi: 10.1111/apt.70264.
    >> Share

  141. CHIN S, Con D, Hilley P, Corte C, et al
    Systemic Biologics Have Similar Safety to Vedolizumab in Inflammatory Bowel Disease Patients Following Liver Transplantation.
    Aliment Pharmacol Ther. 2025 Jul 15. doi: 10.1111/apt.70283.
    >> Share

  142. KOCHAR B, Ananthakrishnan A
    Editorial: Are Antidepressant Medications Safe in Inflammatory Bowel Disease? Authors' Reply.
    Aliment Pharmacol Ther. 2025 Jul 11. doi: 10.1111/apt.70274.
    >> Share

  143. COATES MD, Yadav S, Bielefeldt K
    Editorial: Are Antidepressant Medications Safe in Inflammatory Bowel Disease?
    Aliment Pharmacol Ther. 2025 Jul 11. doi: 10.1111/apt.70258.
    >> Share

  144. CHETWOOD JD, Arzivian A, Tran Y, Paramsothy S, et al
    Meta-Analysis: Intravenous Versus Subcutaneous Infliximab in Inflammatory Bowel Disease.
    Aliment Pharmacol Ther. 2025 Jul 10. doi: 10.1111/apt.70267.
    >> Share

  145. CLOUGH J, Patel K, Honap S
    Editorial: JAK to JAK-Navigating Intraclass JAK Inhibitor Switching in Inflammatory Bowel Disease.
    Aliment Pharmacol Ther. 2025 Jul 9. doi: 10.1111/apt.70226.
    >> Share

  146. CHEN L, Srinivasan A, Choy SW, Van J, et al
    Prescribing Inflammatory Bowel Disease Medications in Chronic Kidney Disease: A Practical Guide.
    Aliment Pharmacol Ther. 2025 Jul 2. doi: 10.1111/apt.70262.
    >> Share

  147. BAILLIE S, Saxena S, Jayasooriya N, Bottle A, et al
    Pain and Sedative Medication Use Among Individuals With Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study.
    Aliment Pharmacol Ther. 2025 Jul 2. doi: 10.1111/apt.70247.
    >> Share

    June 2025
  148. RIGGOTT C, Gracie DJ, Ford AC
    Prevalence and Predictors of Symptoms of Anxiety or Depression at Diagnosis in Patients With Inflammatory Bowel Disease: An Inception Cohort.
    Aliment Pharmacol Ther. 2025 Jun 29. doi: 10.1111/apt.70248.
    >> Share

  149. ROBERTS C, Peters J, Sazonvos A, Goodman N, et al
    Clinical Utility and Cost-Effectiveness of Pretreatment NUDT15 Pharmacogenetic Testing to Prevent Thiopurine-Induced Myelosuppression: A Genotype-First Reverse Phenotyping Cohort Study Within the UK NIHR Inflammatory Bowel Disease Bioresource.
    Aliment Pharmacol Ther. 2025 Jun 23. doi: 10.1111/apt.70232.
    >> Share

  150. SINGH A, Bhardwaj A, Sharma R, Singh D, et al
    Azathioprine or Tofacitinib as Maintenance Therapy in Corticosteroid-Responsive Acute Severe Ulcerative Colitis.
    Aliment Pharmacol Ther. 2025 Jun 20. doi: 10.1111/apt.70246.
    >> Share

  151. LIM J, Rezaie A
    Editorial: Shooting in the Dark-The Problem With Empiric Antispasmodics for Abdominal Pain in Inflammatory Bowel Disease.
    Aliment Pharmacol Ther. 2025 Jun 16. doi: 10.1111/apt.70218.
    >> Share

  152. KOCHAR B, Chaaban L, Kobeissi L, Fuss A, et al
    Outcomes Associated With Anti-Depressant Use in Patients With Inflammatory Bowel Disease.
    Aliment Pharmacol Ther. 2025 Jun 7. doi: 10.1111/apt.70229.
    >> Share

  153. NARDONE OM, Noor NM, Prabhu A, Lim A, et al
    The Effectiveness of Medical Therapies for Joint, Skin and Eye Extraintestinal Manifestations in IBD-An Umbrella Review.
    Aliment Pharmacol Ther. 2025;61:1854-1871.
    >> Share

  154. OSOOLI M, Voghera S, Bruze G, Nordenvall C, et al
    Higher Prescribed Opioid Use Among Adults With Crohn's Disease Than General Population: A Nationwide Cohort Study in Sweden 2006-2021.
    Aliment Pharmacol Ther. 2025 Jun 1. doi: 10.1111/apt.70203.
    >> Share

    May 2025
  155. BARBERIO B, Gracie DJ, Black CJ, Ford AC, et al
    Network Meta-Analysis: Efficacy of Biological Therapies and Small Molecules as Maintenance Therapy in Ulcerative Colitis.
    Aliment Pharmacol Ther. 2025 May 23. doi: 10.1111/apt.70209.
    >> Share

  156. OSTY M, Altwegg R, Serrero M, Benezech A, et al
    Effectiveness and Safety of a Second JAK Inhibitor in Ulcerative Colitis: The J2J Multicentre Study.
    Aliment Pharmacol Ther. 2025 May 22. doi: 10.1111/apt.70199.
    >> Share

  157. IRSHAD M, Irshad S
    Letter: Crohn's Disease With Latent Tuberculosis Infection or Intestinal Tuberculosis: Rapid Discrimination by Targeted Next-Generation Sequencing.
    Aliment Pharmacol Ther. 2025 May 9. doi: 10.1111/apt.70152.
    >> Share

  158. SHINZAKI S, Takagi Y, Sato T
    Editorial: Real-World Effectiveness of Mirikizumab in Ulcerative Colitis-A Valuable but Preliminary Glimpse. Authors' Reply.
    Aliment Pharmacol Ther. 2025 May 5. doi: 10.1111/apt.70180.
    >> Share

  159. AINSWORTH MA, Frimor C
    Editorial: Real-World Effectiveness of Mirikizumab in Ulcerative Colitis-A Valuable but Preliminary Glimpse.
    Aliment Pharmacol Ther. 2025 May 5. doi: 10.1111/apt.70160.
    >> Share

  160. CASANOVA MJ, Rubin de Celix C, Riestra S, Lucendo AJ, et al
    Long-Term Outcomes Following Withdrawal of Anti-Tumour Necrosis Factor Treatment in Inflammatory Bowel Disease Patients in Remission: The Exit Long-Term Study of GETECCU.
    Aliment Pharmacol Ther. 2025 May 2. doi: 10.1111/apt.70172.
    >> Share

  161. CUSSAC C, Riviere P, Altwegg R, Caillo L, et al
    Safety of Advanced Combination Treatment With Selective JAK1 Inhibitors and Biological Therapies in Inflammatory Bowel Diseases: A Real World Experience.
    Aliment Pharmacol Ther. 2025;61:1692-1696.
    >> Share

  162. TAN N, Zampogna C, Lynch K, Hannah N, et al
    Patient Reported Outcomes in Primary Sclerosing Cholangitis: An Australian Perspective.
    Aliment Pharmacol Ther. 2025;61:1612-1621.
    >> Share

    April 2025
  163. FITZPATRICK JA, Gibson PR, Halmos EP
    Editorial: Inflammatory Bowel Disease and Dietary Emulsifiers-A Conundrum That Continues. Authors' Reply.
    Aliment Pharmacol Ther. 2025 Apr 29. doi: 10.1111/apt.70148.
    >> Share

  164. GOLD S, Haskey N, Raman M
    Editorial: Inflammatory Bowel Disease and Dietary Emulsifiers-A Conundrum That Continues.
    Aliment Pharmacol Ther. 2025 Apr 29. doi: 10.1111/apt.70112.
    >> Share

  165. EBRAHIMI R, Ebrahimi F, Niess JH, Mahdi A, et al
    Increased Risk of Cardiovascular Events After Coronary Interventions in Inflammatory Bowel Disease: A Nationwide Matched Cohort Study.
    Aliment Pharmacol Ther. 2025 Apr 29. doi: 10.1111/apt.70162.
    >> Share

  166. MCCURDY JD, Macdonald B, Rosenfeld G, Bessissow T, et al
    Editorial: Seton Use in Perianal Fistulising Crohn's Disease. Authors' Reply.
    Aliment Pharmacol Ther. 2025 Apr 27. doi: 10.1111/apt.70170.
    >> Share

  167. ANAND E, Tozer P
    Editorial: Seton Use in Perianal Fistulising Crohn's Disease.
    Aliment Pharmacol Ther. 2025 Apr 27. doi: 10.1111/apt.70094.
    >> Share

  168. LIU D, Zhong B, Guo L
    Letter: Re-Examining Seton Efficacy in Perianal Crohn's Disease-Considerations for Outcome Measurement and Clinical Interpretation.
    Aliment Pharmacol Ther. 2025 Apr 25. doi: 10.1111/apt.70131.
    >> Share

  169. MCCURDY JD, Macdonald B, Rosenfeld G, Bessissow T, et al
    Letter: Re-Examining Seton Efficacy in Perianal Crohn's Disease-Critical Considerations for Outcome Measurement and Clinical Interpretation. Authors' Reply.
    Aliment Pharmacol Ther. 2025 Apr 25. doi: 10.1111/apt.70153.
    >> Share

  170. RICHARD N, Fumery M
    Editorial: Real-World Evidence of Upadacitinib-An Effective Induction Therapy for Crohn's Disease? Authors' Reply.
    Aliment Pharmacol Ther. 2025 Apr 14. doi: 10.1111/apt.70149.
    >> Share

  171. RAMOS-BELINCHON C, Plevris N
    Editorial: Real-World Evidence of Upadacitinib-An Effective Induction Therapy for Crohn's Disease?
    Aliment Pharmacol Ther. 2025 Apr 14. doi: 10.1111/apt.70113.
    >> Share

  172. KHUNSRIRAKSAKUL C, Ziegler O, Liu D, Kulaylat AS, et al
    The Impact of Antispasmodic Use on Abdominal Pain and Opioid Use in Inflammatory Bowel Disease: A Population-Based Study.
    Aliment Pharmacol Ther. 2025 Apr 11. doi: 10.1111/apt.70147.
    >> Share

  173. TAKAGI Y, Sato T, Nishiguchi T, Nogami A, et al
    Real-World Effectiveness and Safety of Mirikizumab Induction Therapy in Patients With Ulcerative Colitis: A Multicentre Retrospective Observational Study.
    Aliment Pharmacol Ther. 2025 Apr 9. doi: 10.1111/apt.70140.
    >> Share

  174. MEYER A, Amiot A
    Letter: Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis. Authors' Reply.
    Aliment Pharmacol Ther. 2025 Apr 8. doi: 10.1111/apt.70138.
    >> Share

  175. ZHOU Z, Sun N, Liu Q
    Letter: Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis.
    Aliment Pharmacol Ther. 2025 Apr 8. doi: 10.1111/apt.70124.
    >> Share

  176. ALSAKARNEH S, Al Ta'ani O, Aburumman R, Mikhail I, et al
    Risk of De Novo Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis Treated With IL-17A Inhibitors: A Population-Based Study.
    Aliment Pharmacol Ther. 2025 Apr 7. doi: 10.1111/apt.70139.
    >> Share

  177. DESAI A, Sehgal P
    Editorial: Obesity and Outcomes on Advanced Therapy in Ulcerative Colitis-The Fat of the Matter: Authors' Reply.
    Aliment Pharmacol Ther. 2025 Apr 3. doi: 10.1111/apt.70125.
    >> Share

  178. KURIAKOSE KUZHIYANJAL AJ, Limdi JK
    Editorial: Obesity and Outcomes on Advanced Therapy in Ulcerative Colitis-The Fat of the Matter.
    Aliment Pharmacol Ther. 2025 Apr 3. doi: 10.1111/apt.70097.
    >> Share

  179. MELTON S, Swaminathan A, Fitzpatrick J
    Letter: Exclusive Enteral Nutrition in Ulcerative Colitis-The Path Ahead Needs Careful Consideration.
    Aliment Pharmacol Ther. 2025 Apr 1. doi: 10.1111/apt.70091.
    >> Share

  180. XU ZC, Tan E, Garg M
    Letter: The Simple Endoscopic Score for Predicting Crohn's Disease Progression-Not as Simple as It Sounds.
    Aliment Pharmacol Ther. 2025 Apr 1. doi: 10.1111/apt.70108.
    >> Share

  181. CHU MKW, Day AS, Broad L, Costello SP, et al
    Letter: Exclusive Enteral Nutrition in Ulcerative Colitis-The Path Ahead Needs Careful Consideration. Authors' Reply.
    Aliment Pharmacol Ther. 2025 Apr 1. doi: 10.1111/apt.70121.
    >> Share

    March 2025
  182. MASSOURIDIS B, Swaminathan A
    Editorial: Cumulative Impact of Clinical Disease Activity, Biochemical Activity and Psychological Health on the Natural History of Inflammatory Bowel Disease During 8 Years of Longitudinal Follow-Up.
    Aliment Pharmacol Ther. 2025 Mar 22. doi: 10.1111/apt.70086.
    >> Share

  183. RIGGOTT C, Fairbrass KM, Gracie DJ, Ford AC, et al
    Editorial: Cumulative Impact of Clinical Disease Activity, Biochemical Activity and Psychological Health on the Natural History of Inflammatory Bowel Disease During 8 Years of Longitudinal Follow-Up. Authors' Reply.
    Aliment Pharmacol Ther. 2025 Mar 21. doi: 10.1111/apt.70100.
    >> Share

  184. JOUDAKI S, Oladipupo O, Carbery I, Lenti MV, et al
    Meta-Analysis: Pregnancies With Inflammatory Bowel Disease Complicated by Intrahepatic Cholestasis of Pregnancy.
    Aliment Pharmacol Ther. 2025 Mar 20. doi: 10.1111/apt.70096.
    >> Share

  185. MCCURDY J, Munir J, Parlow S, Sambhi G, et al
    The Impact of Setons on Perianal Fistula Outcomes in Patients With Crohn's Disease Treated With Anti-TNF Therapy: A Multicentre Study.
    Aliment Pharmacol Ther. 2025 Mar 18. doi: 10.1111/apt.70081.
    >> Share

  186. HO FF, Wu IX, Chung VCH
    Editorial: Can We Prevent Inflammatory Bowel Disease? Authors' Reply.
    Aliment Pharmacol Ther. 2025 Mar 17. doi: 10.1111/apt.70093.
    >> Share

  187. HO AHY, Mak JWY
    Editorial: Can We Prevent Inflammatory Bowel Disease?
    Aliment Pharmacol Ther. 2025 Mar 17. doi: 10.1111/apt.70071.
    >> Share

  188. STRANGES V, Crowley E
    Editorial: Upadacitinib-A Promising Induction Agent for Paediatric Crohn's Disease?
    Aliment Pharmacol Ther. 2025 Mar 12. doi: 10.1111/apt.70076.
    >> Share

  189. HJALTE V, Myrelid P, Hjortswang H, Rejler M, et al
    Substantial Reduction of Systemic Corticosteroid Use After Primary Ileocaecal Resection in Swedish Patients With Crohn's Disease: A Population-Based Cohort Study.
    Aliment Pharmacol Ther. 2025 Mar 10. doi: 10.1111/apt.70069.
    >> Share

  190. RIGGOTT C, Fairbrass KM, Gracie DJ, Ford AC, et al
    Cumulative Impact of Clinical Disease Activity, Biochemical Activity and Psychological Health on the Natural History of Inflammatory Bowel Disease During 8 Years of Longitudinal Follow-Up.
    Aliment Pharmacol Ther. 2025 Mar 9. doi: 10.1111/apt.70068.
    >> Share

  191. RICHARD N, Amiot A, Seksik P, Altwegg R, et al
    Effectiveness and Safety of Upadacitinib Induction Therapy for 223 Patients With Crohn's Disease: A GETAID Multicentre Cohort Study.
    Aliment Pharmacol Ther. 2025 Mar 4. doi: 10.1111/apt.70073.
    >> Share

  192. AMIOT A, Meyer A, Carbonnel F
    Editorial: Can We Modify the Development and Disease Course of Inflammatory Bowel Disease by Diet? Author's Reply.
    Aliment Pharmacol Ther. 2025 Mar 4. doi: 10.1111/apt.70070.
    >> Share

  193. MAK JWY
    Editorial: Can We Modify the Development and Disease Course of Inflammatory Bowel Disease by Diet?
    Aliment Pharmacol Ther. 2025 Mar 4. doi: 10.1111/apt.70000.
    >> Share

    February 2025
  194. CASSINOTTI A, Canova L
    Editorial: Surveillance Colonoscopy for Detection of Neoplasia in Inflammatory Bowel Disease-Is Dye-Based Chromoendoscopy Always the Final Answer?
    Aliment Pharmacol Ther. 2025 Feb 25. doi: 10.1111/apt.70027.
    >> Share

  195. SHEHAB M, Al-Hindawi A, Bessissow T
    Editorial: Surveillance Colonoscopy for Detection of Neoplasia in Inflammatory Bowel Disease-Is Dye-Based Chromoendoscopy Always the Final Answer? Authors' Reply.
    Aliment Pharmacol Ther. 2025 Feb 25. doi: 10.1111/apt.70057.
    >> Share

  196. KELM M, Flemming S
    Letter in Response to: 'Early Ileal Resection in Crohn's Disease Is Not Associated With Severe Long-Term Outcomes: The ERIC Study'.
    Aliment Pharmacol Ther. 2025 Feb 24. doi: 10.1111/apt.70013.
    >> Share

  197. GRELLIER N, Kirchgesner J, Seksik P
    Letter: Early Ileal Resection in Crohn's Disease Is Not Associated With Severe Long-Term Outcomes: The ERIC Study: Authors' Reply.
    Aliment Pharmacol Ther. 2025 Feb 24. doi: 10.1111/apt.70052.
    >> Share

  198. FITZPATRICK JA, Gibson PR, Taylor KM, Anderson EJ, et al
    Clinical Trial: The Effects of Emulsifiers in the Food Supply on Disease Activity in Crohn's Disease: An Exploratory Double-Blinded Randomised Feeding Trial.
    Aliment Pharmacol Ther. 2025 Feb 18. doi: 10.1111/apt.70041.
    >> Share

  199. HO FF, Gao YY, Chen Y, Wang BH, et al
    Association of Healthy Lifestyle Behaviours With Incident Inflammatory Bowel Disease: A Population-Based Prospective Cohort Study.
    Aliment Pharmacol Ther. 2025 Feb 17. doi: 10.1111/apt.70031.
    >> Share

  200. MENDOLARO M, Daperno M
    Editorial: Endoscopic Activity is an Essential Tool for Patients' Management, Even in Mild Crohn's Disease.
    Aliment Pharmacol Ther. 2025 Feb 15. doi: 10.1111/apt.70015.
    >> Share

  201. EGLINTON T
    Editorial: Examining Perianal Fistulising Crohn's Disease Through the Lens of Wound Repair.
    Aliment Pharmacol Ther. 2025 Feb 15. doi: 10.1111/apt.70001.
    >> Share

  202. COHEN S, Spencer EA, Dolinger MT, Suskind DL, et al
    Upadacitinib for Induction of Remission in Paediatric Crohn's Disease: An International Multicentre Retrospective Study.
    Aliment Pharmacol Ther. 2025 Feb 8. doi: 10.1111/apt.70016.
    >> Share

  203. WEINER BC
    Letter: Clinical Trial Design Considerations for Hospitalised Patients With Ulcerative Colitis Flares and Application to Study Hyperbaric Oxygen Therapy in the NIDDK HBOT-UC Consortium.
    Aliment Pharmacol Ther. 2025 Feb 4. doi: 10.1111/apt.18450.
    >> Share

  204. YE L, Cao Y, Fu Y, Tian C, et al
    Crohn's Disease With Latent Tuberculosis Infection or Intestinal Tuberculosis: Rapid Discrimination by Targeted Next-Generation Sequencing.
    Aliment Pharmacol Ther. 2025 Feb 4. doi: 10.1111/apt.18522.
    >> Share

    January 2025
  205. BARTEL C, Minar P
    Editorial: Baseline Drug Clearance Predicts Outcomes in Children With Inflammatory Bowel Disease Treated With Vedolizumab.
    Aliment Pharmacol Ther. 2025 Jan 31. doi: 10.1111/apt.18519.
    >> Share

  206. TEN BOKKEL HUININK S, Bak MTJ, Beelen EMJ, Erler NS, et al
    The Impact of Postoperative Prophylactic Medication on Long-Term Surgical, Severe Endoscopic and Endoscopic or Radiologic Recurrence Following Primary Ileocecal Resection in Patients With Crohn's Disease.
    Aliment Pharmacol Ther. 2025 Jan 24. doi: 10.1111/apt.18496.
    >> Share

  207. QIAO L, Yang B
    Editorial: Development and Validation of a Multimodal Machine Learning Model for Diagnosing and Assessing Risk of Crohn's Disease in Patients With Perianal Fistulae: Authors' Reply.
    Aliment Pharmacol Ther. 2025 Jan 24. doi: 10.1111/apt.18516.
    >> Share

  208. PARIAN AM, Schwartz DA
    Editorial: Development and Validation of a Multimodal Machine Learning Model for Diagnosing and Assessing Risk of Crohn's Disease in Patients With Perianal Fistula.
    Aliment Pharmacol Ther. 2025 Jan 24. doi: 10.1111/apt.18490.
    >> Share

  209. DESAI A, Sehgal P, Khataniar H, Lewis JD, et al
    Obesity Is Associated With Worsened Outcomes in Patients With Ulcerative Colitis on Advanced Therapies: A Propensity Matched Cohort Study From the U.S.
    Aliment Pharmacol Ther. 2025 Jan 22. doi: 10.1111/apt.18513.
    >> Share

  210. SHEHAB M, Al-Hindawi A, Alrashed F, Murthy S, et al
    Network Meta-Analysis: Comparison of Endoscopic Dysplasia Detection Technologies in Inflammatory Bowel Disease.
    Aliment Pharmacol Ther. 2025 Jan 18. doi: 10.1111/apt.18500.
    >> Share

  211. CHU MKW, Day AS, Broad L, Costello SP, et al
    Meta-Analysis: Exclusive Enteral Nutrition in Adults With Ulcerative Colitis.
    Aliment Pharmacol Ther. 2025 Jan 16. doi: 10.1111/apt.18495.
    >> Share

  212. MEYER A, Chan SSM, Touvier M, Julia C, et al
    Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis.
    Aliment Pharmacol Ther. 2025 Jan 16. doi: 10.1111/apt.18497.
    >> Share

  213. STEIN R, Turner D, Hussey S, Kawasmi A, et al
    Baseline Drug Clearance Predicts Outcomes in Children With Inflammatory Bowel Disease Treated With Vedolizumab: Results From the VedoKids Prospective Multicentre Study.
    Aliment Pharmacol Ther. 2025 Jan 15. doi: 10.1111/apt.18484.
    >> Share

  214. KOMATSU M, Sagami S, Kobayashi T
    Editorial: Leucine-Rich Alpha-2 Glycoprotein Is Associated With Transmural Inflammation Assessed by Intestinal Ultrasound in Patients With Crohn's Disease: Its Potential in Early-Stage Disease-Authors' Reply.
    Aliment Pharmacol Ther. 2025 Jan 10. doi: 10.1111/apt.18493.
    >> Share

  215. MITCHELL A, Swaminathan A
    Editorial: Leucine-Rich Alpha-2 Glycoprotein Is Associated With Transmural Inflammation Assessed by Intestinal Ultrasound in Patients With Crohn's Disease.
    Aliment Pharmacol Ther. 2025 Jan 10. doi: 10.1111/apt.18463.
    >> Share

  216. WOELFEL S, Brand S
    Editorial: Individualising JAK Inhibitor Selection for Patients With Ulcerative Colitis.
    Aliment Pharmacol Ther. 2025 Jan 8. doi: 10.1111/apt.18476.
    >> Share

  217. AKIYAMA S, Fujii T
    Editorial: Individualising JAK Inhibitor Selection for Patients With Ulcerative Colitis-Authors' Reply.
    Aliment Pharmacol Ther. 2025 Jan 8. doi: 10.1111/apt.18489.
    >> Share

  218. MCFALLS C, Melia J
    Editorial: Striving for Equitable Care in Ulcerative Colitis-Authors' Reply.
    Aliment Pharmacol Ther. 2025 Jan 6. doi: 10.1111/apt.18454.
    >> Share

  219. BARNES EL
    Editorial: Striving for Equitable Care in Ulcerative Colitis.
    Aliment Pharmacol Ther. 2025 Jan 6. doi: 10.1111/apt.18423.
    >> Share

  220. MCCURDY JD, Hartley I, Behrenbruch C, Hart A, et al
    Management of Perianal Fistulizing Crohn's Disease According to Principles of Wound Repair.
    Aliment Pharmacol Ther. 2025 Jan 5. doi: 10.1111/apt.18466.
    >> Share

  221. PERAZA J, Kaper ME, Bargas A, Kim I, et al
    A Simple Endoscopic Score for Crohn's Disease (SES-CD) >/= 7 Predicts Disease Progression.
    Aliment Pharmacol Ther. 2025 Jan 5. doi: 10.1111/apt.18492.
    >> Share

  222. LEE T, Ding N, Chetwood JD
    Editorial: Where to Start in Ulcerative Colitis?
    Aliment Pharmacol Ther. 2025 Jan 2. doi: 10.1111/apt.18475.
    >> Share

  223. CAMMAROTA G, Laterza L, Bibbo S, Fusco W, et al
    Review Article: Green Management of IBD-New Paradigms for an Eco-Friendly Approach.
    Aliment Pharmacol Ther. 2025;61:65-74.
    >> Share

  224. LEONG RW, Sakiris A, Arzivian A, Chetwood JD, et al
    Consensus Statements on Assessments and Vaccinations Prior to Commencement of Advanced Therapies for the Treatment of Inflammatory Bowel Diseases.
    Aliment Pharmacol Ther. 2025;61:132-144.
    >> Share

  225. CARBERY I, Todd O, Hale M, Black CJ, et al
    Meta-Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Diseases.
    Aliment Pharmacol Ther. 2025;61:246-257.
    >> Share

    December 2024
  226. CARBERY I, Todd O, Selinger CP
    Letter: Meta-Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Disease-Authors' Reply.
    Aliment Pharmacol Ther. 2024 Dec 26. doi: 10.1111/apt.18464.
    >> Share

  227. DAI C, Huang YH, Jiang M
    Letter: Meta-Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Disease.
    Aliment Pharmacol Ther. 2024 Dec 26. doi: 10.1111/apt.18428.
    >> Share

  228. XIANG Y, Yang F, Yuan F, Gong Y, et al
    Development and Validation of a Multimodal Machine Learning Model for Diagnosing and Assessing Risk of Crohn's Disease in Patients With Perianal Fistula.
    Aliment Pharmacol Ther. 2024 Dec 18. doi: 10.1111/apt.18455.
    >> Share

  229. HAYNESWORTH A, Yeh KH, Lee HH, Kirkpatrick M, et al
    Long-Term Outcomes of an Infliximab-First Versus Vedolizumab-First Treatment Strategy in Biologic-Naive Patients With Ulcerative Colitis.
    Aliment Pharmacol Ther. 2024 Dec 11. doi: 10.1111/apt.18441.
    >> Share


  230. Correction to 'Stromal Vascular Fraction With Platelet-Rich Plasma Injection During Surgery is Feasible and Safe in Treatment-Refractory Perianal Fistulising Crohn's Disease: A Pilot Study'.
    Aliment Pharmacol Ther. 2024 Dec 9. doi: 10.1111/apt.18388.
    >> Share

  231. MCCURDY JD, Wong SY
    Editorial: Mesenchymal Stem Cell Therapy for Perianal Fistulising Crohn's Disease-Effective or Hype?
    Aliment Pharmacol Ther. 2024 Dec 6. doi: 10.1111/apt.18408.
    >> Share

  232. BACSUR P, Farkas K, Molnar T
    Editorial: Mesenchymal Stem Cell Therapy for Perianal Fistulising Crohn's Disease-Effective or Hype? Authors' Reply.
    Aliment Pharmacol Ther. 2024 Dec 6. doi: 10.1111/apt.18427.
    >> Share

  233. KOMATSU M, Sagami S, Hojo A, Karashima R, et al
    Leucine-Rich Alpha-2 Glycoprotein Is Associated With Transmural Inflammation Assessed by Intestinal Ultrasound in Patients With Crohn's Disease.
    Aliment Pharmacol Ther. 2024 Dec 6. doi: 10.1111/apt.18430.
    >> Share

  234. BACSUR P, Farkas K, Molnar T
    Letter: Real-Life Evaluation of Effectiveness of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease Emphasises Importance of Appropriate Patient Selection and Centre Expertise-Authors' Reply.
    Aliment Pharmacol Ther. 2024 Dec 5. doi: 10.1111/apt.18432.
    >> Share

  235. GAO W, Segal JP
    Letter: Real-Life Evaluation of Effectiveness of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease Emphasises the Importance of Appropriate Patient Selection and Centre Expertise.
    Aliment Pharmacol Ther. 2024 Dec 5. doi: 10.1111/apt.18411.
    >> Share

    November 2024
  236. MCFALLS C, Chaaban L, Melia J
    Black Race is Associated with Decreased Exposure to Advanced Therapies and Worse Outcomes in Individuals with Ulcerative Colitis.
    Aliment Pharmacol Ther. 2024 Nov 30. doi: 10.1111/apt.18405.
    >> Share

  237. SWAMINATHAN A, Sparrow MP, Gearry RB
    Letter: Extending the Measurement of Inflammatory Bowel Disease Severity to Include Patient Important Outcomes-Authors' Reply.
    Aliment Pharmacol Ther. 2024 Nov 29. doi: 10.1111/apt.18421.
    >> Share

  238. FORBES AJ
    Letter: Extending the Measurement of Inflammatory Bowel Disease Severity to Include Patient Important Outcomes.
    Aliment Pharmacol Ther. 2024 Nov 29. doi: 10.1111/apt.18410.
    >> Share

  239. KHAN S, Munir A, Henna F, Fatima SM, et al
    Letter: Critical Insights on a Nationwide Cohort Study of Inflammatory Bowel Disease, Histological Activity and Fracture Risk.
    Aliment Pharmacol Ther. 2024 Nov 28. doi: 10.1111/apt.18336.
    >> Share

  240. ZHAO J, Xue E, Liu Z, Li X, et al
    Editorial: Allostatic Load and Inflammatory Bowel Disease. Authors' Reply.
    Aliment Pharmacol Ther. 2024 Nov 27. doi: 10.1111/apt.18414.
    >> Share

  241. MENDOZA J, Irwin J
    Editorial: Allostatic Load and Inflammatory Bowel Disease.
    Aliment Pharmacol Ther. 2024 Nov 27. doi: 10.1111/apt.18325.
    >> Share

  242. AKIYAMA S, Shimizu H, Tamura A, Yokoyama K, et al
    Comparative Efficacy and Safety of Three Janus Kinase Inhibitors in Ulcerative Colitis: A Real-World Multicentre Study in Japan.
    Aliment Pharmacol Ther. 2024 Nov 22. doi: 10.1111/apt.18406.
    >> Share

  243. PAPAMICHAEL K, Cheifetz AS
    Editorial: Is There a Role for Therapeutic Drug Monitoring of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease?
    Aliment Pharmacol Ther. 2024 Nov 19. doi: 10.1111/apt.18360.
    >> Share

  244. HONG SN, Song JH, Kim SJ, Park YH, et al
    Subcutaneous Infliximab Concentration Thresholds for Mucosal and Transmural Healing in Patients With Crohn's Disease.
    Aliment Pharmacol Ther. 2024 Nov 18. doi: 10.1111/apt.18354.
    >> Share

  245. SCHILDKRAUT T, Ding NJS, Chetwood JD
    Letter: Bowel Preparation Quality in Patients With Crohn's Disease.
    Aliment Pharmacol Ther. 2024 Nov 12. doi: 10.1111/apt.18350.
    >> Share

  246. SOLITANO V, Zou G, Jairath V
    Letter: Bowel Preparation Quality in Patients With Crohn's Disease-Authors' Reply.
    Aliment Pharmacol Ther. 2024 Nov 12. doi: 10.1111/apt.18394.
    >> Share

  247. GAO W, Segal JP
    Understanding Factors Associated With Abdominal Pain in Ulcerative Colitis-No Surprises But the Usual Suspects Need Greater Attention.
    Aliment Pharmacol Ther. 2024 Nov 6. doi: 10.1111/apt.18353.
    >> Share

  248. VAN GILS T, Tornblom H, Hreinsson JP, Jonefjall B, et al
    Editorial: Understanding Factors Associated With Abdominal Pain in Ulcerative Colitis-No Surprises but the Usual Suspects Need Greater Attention. Authors' Reply.
    Aliment Pharmacol Ther. 2024 Nov 6. doi: 10.1111/apt.18380.
    >> Share

  249. GEARRY RB, Seow CH, Subramanian S
    Inflammatory bowel disease in 2024 and beyond.
    Aliment Pharmacol Ther. 2024;60:1164-1165.
    >> Share

  250. CHAEMSUPAPHAN T, Leong RW, Vande Casteele N, Seow CH, et al
    Review article: Optimisation of biologic (monoclonal antibody) therapeutic response in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2024;60:1234-1243.
    >> Share

  251. SWAMINATHAN A, Day AS, Sparrow MP, Peyrin-Biroulet L, et al
    Review article: Measuring disease severity in inflammatory bowel disease - Beyond treat to target.
    Aliment Pharmacol Ther. 2024;60:1176-1199.
    >> Share

  252. M NOOR N, Bourke A, Subramanian S
    Review article: Novel therapies in inflammatory bowel disease - An update for clinicians.
    Aliment Pharmacol Ther. 2024;60:1244-1260.
    >> Share

  253. BRONZE S, Agrawal M, Colombel JF, Torres J, et al
    Review article: Prevention of inflammatory bowel disease-The path forward.
    Aliment Pharmacol Ther. 2024;60:1166-1175.
    >> Share

  254. CLASSEN M, Schiller B, Dabritz J
    Predicting complications in paediatric ulcerative colitis: A longitudinal multicentre cohort study.
    Aliment Pharmacol Ther. 2024;60:1421-1434.
    >> Share

    October 2024
  255. WOELFEL S, Dutschler J, Junker D, Konig M, et al
    XBB.1.5-Adapted COVID-19 mRNA Vaccines but Not Infections With Previous Omicron Variants Boost Neutralisation Against the SARS-CoV-2 JN.1 Variant in Patients With Inflammatory Bowel Disease.
    Aliment Pharmacol Ther. 2024 Oct 29. doi: 10.1111/apt.18349.
    >> Share

  256. BACSUR P, Shaham D, Serclova Z, Resal T, et al
    Evaluation of the Effectiveness and Safety of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease: An International Real-Life Retrospective Multicentre Cohort Study.
    Aliment Pharmacol Ther. 2024 Oct 28. doi: 10.1111/apt.18359.
    >> Share

  257. MARILD K, Lerchova T, Ostensson M, Imberg H, et al
    Early-Life Infections, Antibiotics and Later Risk of Childhood and Early Adult-Onset Inflammatory Bowel Disease: Pooled Analysis of Two Scandinavian Birth Cohorts.
    Aliment Pharmacol Ther. 2024 Oct 25. doi: 10.1111/apt.18358.
    >> Share


  258. Correction to 'A Personalised Algorithm Predicting the Risk of Intravenous Corticosteroid Failure in Acute Ulcerative Colitis'.
    Aliment Pharmacol Ther. 2024 Oct 24. doi: 10.1111/apt.18357.
    >> Share

  259. VAN GILS T, Tornblom H, Hreinsson JP, Jonefjall B, et al
    Factors Associated With Abdominal Pain in Patients With Active and Quiescent Ulcerative Colitis: A Multicohort Study.
    Aliment Pharmacol Ther. 2024 Oct 23. doi: 10.1111/apt.18344.
    >> Share

  260. CLASSEN M, Schiller B, Dabritz J
    Letter: Enhancing Predictive Models for Paediatric Ulcerative Colitis-Addressing Socioeconomic, Environmental and Clinical Factors. Authors' Reply.
    Aliment Pharmacol Ther. 2024 Oct 18. doi: 10.1111/apt.18348.
    >> Share

  261. LUO A
    Letter: Enhancing Predictive Models for Paediatric Ulcerative Colitis-Addressing Socioeconomic, Environmental and Clinical Factors.
    Aliment Pharmacol Ther. 2024 Oct 18. doi: 10.1111/apt.18327.
    >> Share

  262. BOGATIC D, Bryant RV
    Letter: Gut microbiota-An overlooked therapeutic target in the prevention of post-operative recurrence of Crohn's disease.
    Aliment Pharmacol Ther. 2024 Oct 17. doi: 10.1111/apt.18258.
    >> Share

  263. KHARAL M, Shahbaz MH, Nadeem MS, Shahbaz S, et al
    Letter: Allostatic load-A potential key in the development of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2024 Oct 17. doi: 10.1111/apt.18270.
    >> Share

  264. DULAI PS, Bonner LB, Sadler C, Raffals LE, et al
    Clinical Trial Design Considerations for Hospitalised Patients With Ulcerative Colitis Flares and Application to Study Hyperbaric Oxygen Therapy in the NIDDK HBOT-UC Consortium.
    Aliment Pharmacol Ther. 2024 Oct 15. doi: 10.1111/apt.18326.
    >> Share

  265. MOCCI G, Tursi A
    Editorial: Effectiveness and safety of ustekinumab in ulcerative colitis-Where we are now.
    Aliment Pharmacol Ther. 2024 Oct 7. doi: 10.1111/apt.18272.
    >> Share

  266. PILLAY L, Christensen B
    Editorial: Re-evaluating early surgery in Ileocaecal Crohn's disease.
    Aliment Pharmacol Ther. 2024 Oct 7. doi: 10.1111/apt.18290.
    >> Share

  267. GRELLIER N, Kirchgesner J, Seksik P
    Editorial: Re-Evaluating Early Surgery in Ileocaecal Crohn's Disease. Author's Reply.
    Aliment Pharmacol Ther. 2024 Oct 7. doi: 10.1111/apt.18320.
    >> Share

  268. CHAPARRO M, Gisbert JP
    Editorial: Effectiveness and Safety of Ustekinumab in Ulcerative Colitis-Where We Are Now in Real Life. Authors' Reply.
    Aliment Pharmacol Ther. 2024 Oct 7. doi: 10.1111/apt.18316.
    >> Share

  269. ZHAO J, Xue E, Liu Z, Li X, et al
    Letter: Allostatic Load and Adverse Prognosis in Inflammatory Bowel Disease-Need More Evidence. Authors' Reply.
    Aliment Pharmacol Ther. 2024 Oct 5. doi: 10.1111/apt.18303.
    >> Share

  270. XU L, Guan C, Zhao L, Xu Y, et al
    Letter: Allostatic load and adverse prognosis in inflammatory bowel disease-Need more evidence.
    Aliment Pharmacol Ther. 2024 Oct 5. doi: 10.1111/apt.18249.
    >> Share

  271. ESTEVINHO MM, Sousa-Pinto B, Moreira PL, Solitano V, et al
    Network Meta-Analysis: Histologic and Histo-Endoscopic Improvement and Remission With Advanced Therapy in Ulcerative Colitis.
    Aliment Pharmacol Ther. 2024 Oct 5. doi: 10.1111/apt.18315.
    >> Share

  272. RIGGOTT C, Ford AC, Gracie DJ
    Review article: The role of the gut-brain axis in inflammatory bowel disease and its therapeutic implications.
    Aliment Pharmacol Ther. 2024 Oct 5. doi: 10.1111/apt.18192.
    >> Share

  273. GREEN Z, Ashton JJ
    Editorial: Prediction in Inflammatory Bowel Disease-Do the Answers Lie in Big Clinical Data?
    Aliment Pharmacol Ther. 2024 Oct 5. doi: 10.1111/apt.18301.
    >> Share

  274. MOLINARO A, de Ridder L
    Editorial: Distinct Challenges of Paediatric From Adult-Onset Inflammatory Bowel Disease, Implications of Aggressive Disease Phenotypes and Early Biologic Therapy in Children.
    Aliment Pharmacol Ther. 2024 Oct 4. doi: 10.1111/apt.18299.
    >> Share

  275. GRANOT M, Weiss B, Haberman Y
    Editorial: Distinct Challenges of Paediatric From Adult-Onset Inflammatory Bowel Disease, Implications of Aggressive Disease Phenotypes and Early Biologic Therapy in Children-Authors' Reply.
    Aliment Pharmacol Ther. 2024 Oct 4. doi: 10.1111/apt.18310.
    >> Share

    September 2024
  276. ZAMANI M, Alizadeh-Tabari S, Murad MH, Singh S, et al
    Meta-analysis: Risk of lymphoma in patients with inflammatory bowel disease in population-based cohort studies.
    Aliment Pharmacol Ther. 2024 Sep 23. doi: 10.1111/apt.18277.
    >> Share

  277. MARILD K, Soderling J, Axelrad J, Halfvarson J, et al
    A nationwide cohort study of inflammatory bowel disease, histological activity and fracture risk.
    Aliment Pharmacol Ther. 2024 Sep 23. doi: 10.1111/apt.18275.
    >> Share

  278. SOLITANO V, Ma C, Jairath V
    Editorial: Advancing care in Crohn's disease-Time to standardise bowel preparation scales. Authors' reply.
    Aliment Pharmacol Ther. 2024 Sep 19. doi: 10.1111/apt.18288.
    >> Share

  279. SHEHAB M, Bessissow T
    Editorial: Advancing care in Crohn's disease-Time to standardise bowel preparation scales.
    Aliment Pharmacol Ther. 2024 Sep 19. doi: 10.1111/apt.18269.
    >> Share

  280. CHAPARRO M, Hermida S, Acosta D, Fernandez-Clotet A, et al
    Long-term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study.
    Aliment Pharmacol Ther. 2024 Sep 17. doi: 10.1111/apt.18230.
    >> Share

  281. GRANOT M, Kopylov U, Loberman-Nachum N, Krauthammer A, et al
    Differences in disease characteristics and treatment exposures between paediatric and adult-onset inflammatory bowel disease using a registry-based cohort.
    Aliment Pharmacol Ther. 2024 Sep 10. doi: 10.1111/apt.18264.
    >> Share

  282. GRELLIER N, Kirchgesner J, Uzzan M, McLellan P, et al
    Early ileal resection in Crohn's disease is not associated with severe long-term outcomes: The ERIC study.
    Aliment Pharmacol Ther. 2024 Sep 5. doi: 10.1111/apt.18247.
    >> Share

  283. PAL P, Mateen MA, Pooja K, Marri UK, et al
    Leveraging existing mid-end ultrasound machine for point-of-care intestinal ultrasound in low-resource settings: Prospective, real-world impact on clinical decision-making.
    Aliment Pharmacol Ther. 2024;60:633-647.
    >> Share

  284. FERREIRO-IGLESIAS R, Porto Silva S, Marin S, Casanova MJ, et al
    Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry.
    Aliment Pharmacol Ther. 2024;60:604-612.
    >> Share

  285. LING LUNDSTROM M, Peterson C, Hedin CRH, Bergemalm D, et al
    Faecal biomarkers for diagnosis and prediction of disease course in treatment-naive patients with IBD.
    Aliment Pharmacol Ther. 2024;60:765-777.
    >> Share

    August 2024
  286. JIANG F, Yang W, Cao Y, Cao X, et al
    The contribution of dietary advanced glycation end-products and genetic risk in the development of inflammatory bowel disease: a prospective cohort study.
    Aliment Pharmacol Ther. 2024 Aug 23. doi: 10.1111/apt.18218.
    >> Share

  287. ZHAO J, Xue E, Zhou S, Zhang M, et al
    Allostatic load increases the incidence and risk of adverse prognosis in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2024 Aug 21. doi: 10.1111/apt.18217.
    >> Share

  288. GIBSON PR, Yao CK, Halmos EP
    Review article: Evidence-based dietary management of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2024 Aug 20. doi: 10.1111/apt.18214.
    >> Share

  289. SOLITANO V, Siegel CA, Korzenik JR, Maratt JK, et al
    Performance of bowel preparation quality scales in patients with Crohn's disease.
    Aliment Pharmacol Ther. 2024 Aug 11. doi: 10.1111/apt.18210.
    >> Share

  290. CROFT A, Okano S, Hartel G, Lord A, et al
    A personalised algorithm predicting the risk of intravenous corticosteroid failure in acute ulcerative colitis.
    Aliment Pharmacol Ther. 2024 Aug 7. doi: 10.1111/apt.18190.
    >> Share

  291. MATHIAS RM, Bryant RV
    Letter: Light in the lumen-The expanding role of intestinal ultrasound for functional symptoms in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2024 Aug 6. doi: 10.1111/apt.18161.
    >> Share

  292. MUJAGIC Z, Aliu A, Bosch DHCA, Keszthelyi D, et al
    Letter: Light in the lumen-The expanding role of intestinal ultrasound for functional symptoms in inflammatory bowel disease. Authors' reply.
    Aliment Pharmacol Ther. 2024 Aug 6. doi: 10.1111/apt.18196.
    >> Share

  293. SELINGER CP, Baillie S, Pollok R
    Letter: Addressing opioid exposure and associated harms in patients with IBD.
    Aliment Pharmacol Ther. 2024;60:423-424.
    >> Share

  294. CHATTERJEE A, Yadav AI, Sekar A, Singh H, et al
    Letter: Extreme diagnostic delay due to misdiagnosis of gastrointestinal tuberculosis later diagnosed as postoperative Crohn's disease.
    Aliment Pharmacol Ther. 2024;60:537-539.
    >> Share

  295. CROUWEL F, Simsek M, de Boer MA, van Asseldonk DP, et al
    Multicentre study and systematic review: Allopurinol exposure during pregnancy.
    Aliment Pharmacol Ther. 2024;60:503-518.
    >> Share

    July 2024
  296. FEAGAN BG, Matsuoka K, Rogler G, Laharie D, et al
    Long-term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow-up in the SELECTION open-label long-term extension study.
    Aliment Pharmacol Ther. 2024 Jul 31. doi: 10.1111/apt.18158.
    >> Share

  297. SEQUIER L, Caron B, Loeuille D, Honap S, et al
    Systematic review: Methotrexate-A poorly understood and underused medication in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2024 Jul 30. doi: 10.1111/apt.18194.
    >> Share

  298. LAN Q, Guo L, Xiong Z
    Letter: Critical appraisal of biologic therapy in management of early ulcerative colitis-Addressing study limitations and the role of psychological resilience.
    Aliment Pharmacol Ther. 2024 Jul 28. doi: 10.1111/apt.18156.
    >> Share

  299. STRANDE V, Hoivik ML, Kristensen VA
    Letter: Critical appraisal of biologic therapy in early ulcerative colitis management-Addressing study limitations and the role of psychological resilience-Authors' reply.
    Aliment Pharmacol Ther. 2024 Jul 28. doi: 10.1111/apt.18187.
    >> Share

  300. SCHREIBER S, Cross RK, Panaccione R, D'Haens G, et al
    Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid-free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's disease.
    Aliment Pharmacol Ther. 2024 Jul 25. doi: 10.1111/apt.18184.
    >> Share

  301. ARVANITAKIS K, Germanidis G
    Editorial: GLP-1 receptor agonists in inflammatory bowel disease-Is it time?
    Aliment Pharmacol Ther. 2024 Jul 21. doi: 10.1111/apt.18152.
    >> Share

  302. BOGATIC D, Bryant RV
    Letter: Microbial manipulation for primary sclerosing cholangitis-associated inflammatory bowel disease-hope on the horizon.
    Aliment Pharmacol Ther. 2024 Jul 16. doi: 10.1111/apt.18098.
    >> Share

  303. WEWER MD, Nordestgaard RLM, Malham M, Wewer V, et al
    Editorial: Treatments of inflammatory bowel disease across age-spectrum-Are they the same? Authors' reply.
    Aliment Pharmacol Ther. 2024 Jul 8. doi: 10.1111/apt.18163.
    >> Share

  304. HO AHY, Mak JWY
    Editorial: Treatments for inflammatory bowel disease across the age spectrum-Are they the same?
    Aliment Pharmacol Ther. 2024 Jul 8. doi: 10.1111/apt.18143.
    >> Share

    June 2024
  305. DESAI A, Petrov J, Hashash JG, Patel H, et al
    Use of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2024 Jun 27. doi: 10.1111/apt.18138.
    >> Share

  306. RAO V, Chen G, Koh E, Segal JP, et al
    Letter: Persisting with persistence-Caution as an outcome measure in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2024 Jun 24. doi: 10.1111/apt.18114.
    >> Share

  307. YIU TH, Ko Y, Pudipeddi A, Natale P, et al
    Letter: Persisting with persistence-A caution as an outcome measure in inflammatory bowel disease: Authors' reply.
    Aliment Pharmacol Ther. 2024 Jun 24. doi: 10.1111/apt.18136.
    >> Share

  308. BAK MTJ, Demers K, Hammoudi N, Allez M, et al
    Systematic review: Patient-related, microbial, surgical, and histopathological risk factors for endoscopic post-operative recurrence in patients with Crohn's disease.
    Aliment Pharmacol Ther. 2024 Jun 17. doi: 10.1111/apt.18040.
    >> Share

  309. CHHIBBA T
    Editorial: Surgery to reduce opioid use in Crohn's disease: Does a classic solution address a newer problem?
    Aliment Pharmacol Ther. 2024 Jun 14. doi: 10.1111/apt.18051.
    >> Share

  310. SEO J, Kim S, Hong SW, Hwang SW, et al
    Continuing or stopping 5-aminosalicylates in patients with inflammatory bowel disease on anti-TNF therapy: A nationwide population-based study.
    Aliment Pharmacol Ther. 2024 Jun 12. doi: 10.1111/apt.18102.
    >> Share

  311. ATTAUABI M, Steenholdt C, Poulsen A, Gubatan J, et al
    Network meta-analysis: Comparative onset of early effect of biologics and small molecules in moderately to severely active luminal Crohn's disease.
    Aliment Pharmacol Ther. 2024 Jun 11. doi: 10.1111/apt.18110.
    >> Share

  312. NORDESTGAARD RLM, Wewer MD, Malham M, Wewer V, et al
    Treatment of inflammatory bowel disease with steroid-sparing medications is age-dependent - Results from a Danish nationwide cohort study, 2000-2018.
    Aliment Pharmacol Ther. 2024 Jun 10. doi: 10.1111/apt.18106.
    >> Share

  313. FUKUDA T, Yamazaki H, Matsuoka K
    Editorial: Mucosal healing with steroids-Once upon a time in ulcerative colitis. Authors' reply.
    Aliment Pharmacol Ther. 2024 Jun 9. doi: 10.1111/apt.18111.
    >> Share

  314. BARREIRO-DE ACOSTA M, Rodriguez-Lago I
    Editorial: Mucosal healing with steroids: Once upon a time in ulcerative colitis.
    Aliment Pharmacol Ther. 2024 Jun 9. doi: 10.1111/apt.18094.
    >> Share

  315. GARCIA MJ, Gisbert JP, Chaparro M
    Letter: Third-line therapy in acute severe ulcerative colitis, exploring the uncertainty and unanswered questions-Authors' reply.
    Aliment Pharmacol Ther. 2024 Jun 6. doi: 10.1111/apt.18104.
    >> Share

  316. STRANDE V, Lund C, Hagen M, Bengtson MB, et al
    Clinical course of ulcerative colitis: Frequent use of biologics and low colectomy rate first year after diagnosis-results from the IBSEN III inception cohort.
    Aliment Pharmacol Ther. 2024 Jun 4. doi: 10.1111/apt.18097.
    >> Share

  317. CHETWOOD JD, Ding NS
    Letter: Third-line therapy in acute severe ulcerative colitis, exploring the uncertainty and unanswered questions.
    Aliment Pharmacol Ther. 2024 Jun 3. doi: 10.1111/apt.18056.
    >> Share

  318. SONG S, Lv J, Li L, Pang Y, et al
    Editorial: Exploring the influence of diet on later-onset ulcerative colitis-Are eggs and spicy foods the key factors in Asia? Authors' reply.
    Aliment Pharmacol Ther. 2024;59:1453-1454.
    >> Share

  319. ALIU A, Bosch DHCA, Keszthelyi D, Ardabili AR, et al
    Letter: Intestinal permeability accounting for ongoing gastrointestinal symptoms following endoscopic remission in IBD-Authors' reply.
    Aliment Pharmacol Ther. 2024;59:1646-1647.
    >> Share

  320. LEONG RW, Jairath V, Ma C
    Letter: Intestinal permeability accounting for ongoing gastrointestinal symptoms following endoscopic remission in IBD.
    Aliment Pharmacol Ther. 2024;59:1644-1645.
    >> Share

  321. BEATON D, Sharp L, Lu L, Trudgill N, et al
    Diagnostic yield from symptomatic lower gastrointestinal endoscopy in the UK: A British Society of Gastroenterology analysis using data from the National Endoscopy Database.
    Aliment Pharmacol Ther. 2024;59:1589-1603.
    >> Share

    May 2024
  322. DUTT K, Vasudevan A
    Editorial: Exclusive enteral nutrition: Positioning in the ever-growing landscape of inflammatory bowel disease therapy.
    Aliment Pharmacol Ther. 2024 May 23. doi: 10.1111/apt.18055.
    >> Share

  323. ALAHMAD M, Quraishi MN, Khan SW, Omar NM, et al
    Letter: Early real-world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease.
    Aliment Pharmacol Ther. 2024 May 23. doi: 10.1111/apt.18049.
    >> Share

  324. YIU TH, Ko Y, Pudipeddi A, Natale P, et al
    Letter: Early real-world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease-Authors' reply.
    Aliment Pharmacol Ther. 2024 May 23. doi: 10.1111/apt.18057.
    >> Share

  325. VUIJK SA, de Ridder L
    Editorial: Infliximab induction therapy in paediatric Crohn's disease: A cost-effective strategy? Authors' reply.
    Aliment Pharmacol Ther. 2024 May 21. doi: 10.1111/apt.18053.
    >> Share

  326. CHANCHLANI N, Russell RK
    Editorial: Infliximab induction therapy in pediatric Crohn's disease-A cost-effective strategy?
    Aliment Pharmacol Ther. 2024 May 21. doi: 10.1111/apt.18033.
    >> Share

  327. PLOTKIN L, Buchuk R, Lujan R, Focht G, et al
    Enteral nutrition compared with corticosteroids in children with Crohn's disease: A long-term nationwide study from the epi-IIRN.
    Aliment Pharmacol Ther. 2024 May 14. doi: 10.1111/apt.18028.
    >> Share

  328. NEDUMANNIL L, Mohamedrashed M, Bohra A, Sood S, et al
    Letter: The emerging role of novel capsule endoscopy systems in gastroenterology with specific reference to small bowel Crohn's disease.
    Aliment Pharmacol Ther. 2024;59:1162-1163.
    >> Share

  329. BARTH I, Stevens CL, Strokap CJ, Campmans-Kuijpers MJE, et al
    Letter: Diet-microbiome interactions in inflammatory bowel disease-Navigating towards individualised dietary strategies.
    Aliment Pharmacol Ther. 2024;59:1154-1155.
    >> Share

  330. THWAITES PA, Gibson PR
    Letter: The emerging role of novel capsule endoscopy systems in gastroenterology with specific reference to small bowel Crohn's disease. Authors' reply.
    Aliment Pharmacol Ther. 2024;59:1164-1165.
    >> Share

  331. SEIDELIN JB
    Editorial: Time to address quality of life in our IBD treatment-IBD nurse intervention as a key part of multimodal IBD management.
    Aliment Pharmacol Ther. 2024;59:1152-1153.
    >> Share

  332. GARCIA MJ, Gisbert JP, Chaparro M
    Editorial: Sequencing rescue therapy for acute severe ulcerative colitis-Ready for revision? Authors' reply.
    Aliment Pharmacol Ther. 2024;59:1298-1299.
    >> Share

  333. DERIKX LAAP, Hoentjen F
    Editorial: Sequencing rescue therapy for acute severe ulcerative colitis-Ready for revision?
    Aliment Pharmacol Ther. 2024;59:1296-1297.
    >> Share

  334. SHAH A, Holtmann G
    Editorial: Is it time to include oral vancomycin in therapeutic guidelines for primary sclerosing cholangitis-associated inflammatory bowel disease?
    Aliment Pharmacol Ther. 2024;59:1290-1291.
    >> Share

  335. NORGARD BM, Thorarinsson CT, Zegers FD, Kjeldsen J, et al
    The use of opioids nine months after surgery for Crohn's disease - a nationwide cohort study.
    Aliment Pharmacol Ther. 2024 May 1. doi: 10.1111/apt.18014.
    >> Share

    April 2024
  336. SONG S, Wu Z, Lv J, Yu C, et al
    Dietary factors and patterns in relation to risk of later-onset ulcerative colitis in Chinese: A prospective study of 0.5 million people.
    Aliment Pharmacol Ther. 2024 Apr 23. doi: 10.1111/apt.17963.
    >> Share

  337. FUKUDA T, Yamazaki H, Miyatani Y, Sawada T, et al
    Recent steroid use and the relapse risk in ulcerative colitis patients with endoscopic healing.
    Aliment Pharmacol Ther. 2024 Apr 23. doi: 10.1111/apt.18013.
    >> Share

  338. YIU TH, Ko Y, Pudipeddi A, Natale P, et al
    Meta-analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2024 Apr 23. doi: 10.1111/apt.18006.
    >> Share

  339. FERNANDEZ-CLOTET A, Ordas I, Masamunt MC, Caballol B, et al
    Magnetic resonance enterography findings 46 weeks after initiation of biological therapy predict long-term adverse outcomes in Crohn's disease.
    Aliment Pharmacol Ther. 2024 Apr 23. doi: 10.1111/apt.17968.
    >> Share

  340. VUIJK SA, Jongsma MME, Hoeven BM, Cozijnsen MA, et al
    Randomised clinical trial: First-line infliximab biosimilar is cost-effective compared to conventional treatment in paediatric Crohn's disease.
    Aliment Pharmacol Ther. 2024 Apr 21. doi: 10.1111/apt.18000.
    >> Share

  341. URQUHART SA, Fletcher JG, Bruining DH
    Editorial: Foretelling the future-Emerging role of magnetic resonance enterography as a prognostic tool in Crohn's disease.
    Aliment Pharmacol Ther. 2024 Apr 21. doi: 10.1111/apt.17991.
    >> Share

  342. OKABAYASHI S, Kobayashi T
    Editorial: Exploring the influence of diet on later-onset ulcerative colitis-Are eggs and spicy foods the key factors in Asia?
    Aliment Pharmacol Ther. 2024 Apr 21. doi: 10.1111/apt.17983.
    >> Share

  343. ARATARI A, Scribano ML, Pugliese D, Baccolini V, et al
    Crohn's disease after surgery: Changes in post-operative management strategies over time and their impact on long-term re-operation rate-A retrospective multicentre real-world study.
    Aliment Pharmacol Ther. 2024 Apr 14. doi: 10.1111/apt.18001.
    >> Share

  344. KIM K, Park JJ, Yoon H, Lee J, et al
    Application of clinical decision support tools for predicting outcomes with vedolizumab therapy in patients with inflammatory bowel disease: A KASID multicentre study.
    Aliment Pharmacol Ther. 2024 Apr 14. doi: 10.1111/apt.17989.
    >> Share

  345. ALIU A, Bosch DHCA, Keszthelyi D, Rezazadeh Ardabili A, et al
    Review article: A practical approach to persistent gastrointestinal symptoms in inflammatory bowel disease in remission.
    Aliment Pharmacol Ther. 2024 Apr 8. doi: 10.1111/apt.17988.
    >> Share

  346. VASUDEVAN A, Con D, van Langenberg DR
    Letter: Thioguanine, an under-utilised option in inflammatory bowel disease? Authors' reply.
    Aliment Pharmacol Ther. 2024;59:1011.
    >> Share

  347. ASONUMA K, Sagami S, Kobayashi T
    Letter: Modifying the Mayo endoscopic subscore for improved prognostic insights.
    Aliment Pharmacol Ther. 2024;59:1005-1006.
    >> Share

  348. CHETWOOD JD, Paramsothy S, Leong RW
    Letter: Thioguanine, an underutilised option in inflammatory bowel disease?
    Aliment Pharmacol Ther. 2024;59:1009-1010.
    >> Share

    March 2024
  349. AKIYAMA S, Yokoyama K, Yagi S, Shinzaki S, et al
    Efficacy and safety of filgotinib for ulcerative colitis: A real-world multicenter retrospective study in Japan.
    Aliment Pharmacol Ther. 2024 Mar 17. doi: 10.1111/apt.17961.
    >> Share

  350. RICCIUTO A, Liu K, El-Matary W, Amin M, et al
    Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis-associated inflammatory bowel disease (PSC-IBD): A matched analysis from the Paediatric PSC Consortium.
    Aliment Pharmacol Ther. 2024 Mar 10. doi: 10.1111/apt.17936.
    >> Share

  351. GARCIA MJ, Riestra S, Amiot A, Julsgaard M, et al
    Effectiveness and safety of a third-line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study).
    Aliment Pharmacol Ther. 2024 Mar 6. doi: 10.1111/apt.17938.
    >> Share

  352. LU C, Rosentreter R, Delisle M, White M, et al
    Systematic review: Defining, diagnosing and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound.
    Aliment Pharmacol Ther. 2024 Mar 4. doi: 10.1111/apt.17918.
    >> Share

  353. GONCZI L, Lakatos L, Ilias A, Lakatos PL, et al
    Editorial: The prevalence and outcomes of perianal Crohn's disease across the treatment eras-Authors' reply.
    Aliment Pharmacol Ther. 2024;59:715-716.
    >> Share

  354. LENFANT M, Verstockt B, Sabino J, Vermeire S, et al
    Letter: Should ulcerative colitis be monitored more or less invasively? Authors' reply.
    Aliment Pharmacol Ther. 2024;59:723-724.
    >> Share

  355. LAHARIE D
    Letter: Should ulcerative colitis be monitored more or less invasively?
    Aliment Pharmacol Ther. 2024;59:721-722.
    >> Share

  356. TASSONE D, Hartley I, Ding NS
    Editorial: The prevalence and outcomes of perianal Crohn's disease across treatment eras.
    Aliment Pharmacol Ther. 2024;59:713-714.
    >> Share

  357. VAN LIERE ELSA, de Boer NKH
    Editorial: Towards optimal thiopurine therapy for inflammatory bowel disease.
    Aliment Pharmacol Ther. 2024;59:792-793.
    >> Share

  358. VASUDEVAN A, Con D, van Langenberg DR
    Editorial: Towards optimal thiopurine therapy for inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2024;59:794.
    >> Share

  359. BOKEMEYER B, Plachta-Danielzik S, Steiner IM, Pohlschneider D, et al
    Inflammatory bowel disease (IBD) patients with impaired quality of life on biologic therapy benefit from the support of an IBD nurse specialist: Results of a randomised controlled trial in Germany (IBD(BIO-ASSIST) study).
    Aliment Pharmacol Ther. 2024 Mar 1. doi: 10.1111/apt.17926.
    >> Share

    February 2024
  360. ERIKSSON C, Sun J, Bryder M, Broms G, et al
    Impact of inflammatory bowel disease on the risk of acute coronary syndrome: A Swedish Nationwide Cohort Study.
    Aliment Pharmacol Ther. 2024 Feb 29. doi: 10.1111/apt.17932.
    >> Share

  361. ZAMANI M, Alizadeh-Tabari S, Murad MH, Ananthakrishnan AN, et al
    Meta-analysis: Risk of pancreatic cancer in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2024 Feb 19. doi: 10.1111/apt.17919.
    >> Share

  362. SAGAMI S, Kobayashi T
    Editorial: Extending upadacitinib induction dosing in ulcerative colitis-A delicate balance of efficacy and safety.
    Aliment Pharmacol Ther. 2024;59:579-580.
    >> Share

  363. PANACCIONE R
    Editorial: Extending upadacitinib induction dosing in ulcerative colitis-A delicate balance of efficacy and safety. Author's reply.
    Aliment Pharmacol Ther. 2024;59:581-582.
    >> Share

  364. VASUDEVAN A, Con D, De Cruz P, Sparrow MP, et al
    Clinical trial: Combination allopurinol-thiopurine versus standard thiopurine in patients with IBD escalating to immunomodulators (the DECIDER study).
    Aliment Pharmacol Ther. 2024;59:504-514.
    >> Share

    January 2024
  365. CON D, Srinivasan A
    Letter: Comparing first-line infliximab and vedolizumab for ulcerative colitis-it depends on how you use the drug.
    Aliment Pharmacol Ther. 2024;59:140-141.
    >> Share

  366. VAN DE MEEBERG MM, Fidder HH, de Jonge R, Bouma G, et al
    Editorial: Monitoring methotrexate polyglutamates in Crohn's disease-Authors' reply.
    Aliment Pharmacol Ther. 2024;59:120-121.
    >> Share

  367. BARCLAY ML, Stamp LK
    Editorial: Monitoring methotrexate polyglutamates in Crohn's disease.
    Aliment Pharmacol Ther. 2024;59:118-119.
    >> Share

  368. PRAY C, Narula N
    Editorial: Moving towards prognostic endoscopic scoring in IBD.
    Aliment Pharmacol Ther. 2024;59:132-133.
    >> Share

    December 2023
  369. GONCZI L, Lakatos L, Golovics PA, Angyal D, et al
    Burden of perianal disease in Crohn's disease: Accelerating medical therapy and high rates of perianal surgery over the last four decades - Results from a population-based study over four decades.
    Aliment Pharmacol Ther. 2023 Dec 19. doi: 10.1111/apt.17836.
    >> Share

  370. MEYER A, Dong C, Chan SSM, Touvier M, et al
    Dietary index based on the Food Standards Agency nutrient profiling system and risk of Crohn's disease and ulcerative colitis.
    Aliment Pharmacol Ther. 2023 Dec 15. doi: 10.1111/apt.17835.
    >> Share

  371. DESAI A, Regueiro M, Kochhar GS
    Letter: Tofacitinib, vedolizumab and ustekinumab in patients with ulcerative colitis-Authors' reply.
    Aliment Pharmacol Ther. 2023;58.
    >> Share

  372. SOHN J
    Editorial: Unravelling the relationship between periodontal disease and inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023;58.
    >> Share

  373. REZAZADEH ARDABILI A, Janssen L, Mujagic Z
    Letter: Abdominal pain in patients with inflammatory bowel disease in remission - A look beyond psychosocial factors. Authors' reply.
    Aliment Pharmacol Ther. 2023;58.
    >> Share

  374. CHANG HC, Gau SY
    Letter: Tofacitinib, vedolizumab and ustekinumab in patients with ulcerative colitis.
    Aliment Pharmacol Ther. 2023;58.
    >> Share

  375. BASSOTTI G, Villanacci V, Maconi G
    Letter: Abdominal pain in inflammatory bowel disease patients in remission-A look beyond psychosocial factors.
    Aliment Pharmacol Ther. 2023;58.
    >> Share

    November 2023
  376. BUISSON A, Nachury M, Bazoge M, Yzet C, et al
    Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: The REMSWITCH-LT study.
    Aliment Pharmacol Ther. 2023 Nov 30. doi: 10.1111/apt.17822.
    >> Share

  377. PEYRIN-BIROULET L, Vermeire S, D'Haens G, Panes J, et al
    Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long-term extension period of STARDUST.
    Aliment Pharmacol Ther. 2023 Nov 30. doi: 10.1111/apt.17751.
    >> Share

  378. PANACCIONE R, Danese S, Zhou W, Klaff J, et al
    Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis.
    Aliment Pharmacol Ther. 2023 Nov 27. doi: 10.1111/apt.17816.
    >> Share

  379. BOKEMEYER B, Plachta-Danielzik S
    Letter: Comparing first-line infliximab and vedolizumab for ulcerative colitis-It depends on how you use the drug. Authors' reply.
    Aliment Pharmacol Ther. 2023 Nov 4. doi: 10.1111/apt.17796.
    >> Share

  380. KELLER JJ, Terveer EM
    Editorial: Continuous monitoring to improve outcome of treatment-the next step towards safe and effective faecal microbiota transplantation.
    Aliment Pharmacol Ther. 2023;58:946-947.
    >> Share

  381. DAN L, Wang X, Chen J
    Editorial: Unravelling the fibres-low dietary fibre may lower risk of developing IBD. Authors' reply.
    Aliment Pharmacol Ther. 2023;58:940-941.
    >> Share

  382. LOPES EW, Khalili H
    Editorial: Unravelling the fibres-low dietary fibre may lower risk of developing IBD.
    Aliment Pharmacol Ther. 2023;58:938-939.
    >> Share

    October 2023
  383. SPARTZ EJ, DeDecker LC, Fansiwala KM, Noorian S, et al
    Recent trends and risk factors associated with Clostridioides difficile infections in hospitalized patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023 Oct 24. doi: 10.1111/apt.17777.
    >> Share

  384. LENFANT M, Verstockt B, Sabino J, Vermeire S, et al
    The assessment of segmental healing by the Modified Mayo Endoscopic Score (MMES) complements the prediction of long-term clinical outcomes in patients with ulcerative colitis.
    Aliment Pharmacol Ther. 2023 Oct 16. doi: 10.1111/apt.17753.
    >> Share

  385. DAJTI E, Frazzoni L, Iascone V, Secco M, et al
    Systematic review with meta-analysis: Diagnostic performance of faecal calprotectin in distinguishing inflammatory bowel disease from irritable bowel syndrome in adults.
    Aliment Pharmacol Ther. 2023 Oct 12. doi: 10.1111/apt.17754.
    >> Share

  386. KAYAL M, Meringer H, Martin L, Colombel JF, et al
    Scores used to predict outcomes in acute severe ulcerative colitis: A systematic review.
    Aliment Pharmacol Ther. 2023 Oct 11. doi: 10.1111/apt.17731.
    >> Share

  387. RIGGOTT C, Fairbrass KM, Black CJ, Gracie DJ, et al
    Novel symptom clusters predict disease impact and healthcare utilisation in inflammatory bowel disease: Prospective longitudinal follow-up study.
    Aliment Pharmacol Ther. 2023 Oct 4. doi: 10.1111/apt.17735.
    >> Share

  388. WILLIAMS KM, Challa PK, Lopes EW, Burke KE, et al
    Periodontal disease is not associated with risk of inflammatory bowel disease: Results from two prospective cohort studies in the US.
    Aliment Pharmacol Ther. 2023 Oct 2. doi: 10.1111/apt.17732.
    >> Share

  389. TASSONE D, Hartley I, Ding NS
    Letter: Muscle thickness measurement using ultrasound-A step closer to the use of body composition analysis in the management of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023;58:729-730.
    >> Share

  390. ANDREW B, Zhou A, Trinh S, Srinivasan A, et al
    Letter: Antibiotics in gut dysbiosis and development of inflammatory bowel disease-More thought is needed.
    Aliment Pharmacol Ther. 2023;58:838-839.
    >> Share

  391. OH SJ, Kim HJ, Lee CK
    Letter: Antibiotics in gut dysbiosis and development of inflammatory bowel disease-More thought is needed-Authors' reply.
    Aliment Pharmacol Ther. 2023;58:840-841.
    >> Share

  392. ARULJOTHY A, Singh S, Narula N, Moran GW, et al
    Systematic review with meta-analysis: Medical therapies for treatment of ulcerative proctitis.
    Aliment Pharmacol Ther. 2023;58:740-762.
    >> Share

  393. REZAZADEH ARDABILI A, Van Bodegraven AA
    Editorial: IBD cost evolution - transitioning from compensating lost productivity to escalating medication expenses.
    Aliment Pharmacol Ther. 2023;58:832-833.
    >> Share

    September 2023
  394. VAN DE MEEBERG MM, Fidder HH, Oldenburg B, Sundaresan J, et al
    Therapeutic drug monitoring of methotrexate in patients with Crohn's disease.
    Aliment Pharmacol Ther. 2023 Sep 28. doi: 10.1111/apt.17719.
    >> Share

  395. FAQERAH N, Walker D, Gerasimidis K
    Review article: The complex interplay between diet and Escherichia coli in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023 Sep 28. doi: 10.1111/apt.17720.
    >> Share

  396. JANSSEN LM, Rezazadeh Ardabili A, Romberg-Camps MJL, Winkens B, et al
    Abdominal pain in patients with inflammatory bowel disease in remission: A prospective study on contributing factors.
    Aliment Pharmacol Ther. 2023 Sep 19. doi: 10.1111/apt.17718.
    >> Share

  397. SCHREIBER S, Rogler G, Watanabe M, Vermeire S, et al
    Integrated safety analysis of filgotinib for ulcerative colitis: Results from SELECTION and SELECTIONLTE.
    Aliment Pharmacol Ther. 2023 Sep 18. doi: 10.1111/apt.17674.
    >> Share

  398. ANDREW B, Srinivasan A, Zhou A, Vasudevan A, et al
    Letter: Elderly onset inflammatory bowel disease-Treat to target approach is still warranted.
    Aliment Pharmacol Ther. 2023;58:556-557.
    >> Share

  399. YAMAMOTO T
    Editorial: Is vedolizumab the preferred biologic therapy for biologic-naive patients with ulcerative colitis?
    Aliment Pharmacol Ther. 2023;58:546-547.
    >> Share

  400. DIGNASS A, Rath S, Kleindienst T, Stallmach A, et al
    Review article: Translating STRIDE-II into clinical reality - Opportunities and challenges.
    Aliment Pharmacol Ther. 2023;58:492-502.
    >> Share

  401. WU X, Yang Y
    Letter: Chinese herbal medicine Curcumin-QingDai (CurQD) - A good treatment option for active ulcerative colitis?
    Aliment Pharmacol Ther. 2023;58:640.
    >> Share

  402. DIGNASS A, Rath S, Kleindienst T, Stallmach A, et al
    Editorial: If STRIDE-II is the hammer, then Crohn's disease and ulcerative colitis are not the same nails-Authors' reply.
    Aliment Pharmacol Ther. 2023;58:634-635.
    >> Share

  403. KEDIA S, Ahuja V
    Editorial: If STRIDE-II is the hammer, then Crohn's disease and ulcerative colitis are not the same nails.
    Aliment Pharmacol Ther. 2023;58:632-633.
    >> Share

  404. YANAI H, Salomon N, Ben-Horin S, Kopylov U, et al
    Letter: Chinese herbal medicine Curcumin-QingDai (CurQD)-A good treatment option for active ulcerative colitis? Authors' reply.
    Aliment Pharmacol Ther. 2023;58:641.
    >> Share

    August 2023
  405. HONAP S, Peyrin-Biroulet L
    Review article: Externally derived control arms-An opportunity for clinical trials in inflammatory bowel disease?
    Aliment Pharmacol Ther. 2023 Aug 21. doi: 10.1111/apt.17684.
    >> Share

  406. EVERHOV AH, Soderling J, Befrits G, Khalili H, et al
    Increasing healthcare costs in inflammatory bowel disease 2007-2020 in Sweden.
    Aliment Pharmacol Ther. 2023 Aug 18. doi: 10.1111/apt.17675.
    >> Share

  407. WOELFEL S, Dutschler J, Konig M, Dulovic A, et al
    STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023 Aug 12. doi: 10.1111/apt.17661.
    >> Share

  408. LOBATON T, Truyens M
    Editorial: LAG-3-depleting monoclonal antibody: a potential treatment for patients with ulcerative colitis?
    Aliment Pharmacol Ther. 2023;58:359-360.
    >> Share

  409. KANE S
    Editorial: Increased risk of cervical dysplasia with immunomodulator use in IBD.
    Aliment Pharmacol Ther. 2023;58:357-358.
    >> Share

  410. KIRCHGESNER J, Beaugerie L
    Editorial: Pip pip to PIPs (post- inflammatory polyps) as a neoplasia risk factor in IBD? Authors' reply.
    Aliment Pharmacol Ther. 2023;58:363.
    >> Share

  411. TASSONE D, Hartley I, Ding NS
    Letter: Combatting sarcopenia to improve clinical outcomes in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023;58:376-377.
    >> Share

  412. VELAYOS FS
    Editorial: Pip pip to PIP's (post-inflammatory polyps) as a neoplasia risk factor in IBD?
    Aliment Pharmacol Ther. 2023;58:361-362.
    >> Share

    July 2023
  413. DENG M, Dan L, Ye S, Chen X, et al
    Higher dietary fibre intake is associated with lower risk of inflammatory bowel disease: prospective cohort study.
    Aliment Pharmacol Ther. 2023 Jul 18. doi: 10.1111/apt.17649.
    >> Share

  414. MIN Y, Wei X, Peng X
    Letter: Mendelian randomization-New perspective in inflammatory bowel disease and pancreatic cancer?
    Aliment Pharmacol Ther. 2023;58:143-144.
    >> Share

  415. MASSIRONI S, Vigano C, Danese S
    Letter: Mendelian randomization - new perspective in inflammatory bowel disease and pancreatic cancer? Authors' reply.
    Aliment Pharmacol Ther. 2023;58:145-146.
    >> Share

  416. MILES M, Nasser Y
    Editorial: faecal incontinence in ulcerative colitis.
    Aliment Pharmacol Ther. 2023;58:114-115.
    >> Share

  417. CHAN P, Connor S, Huang V, Karimi N, et al
    Letter: expanding the role for decision aids in IBD into pregnancy-related topics.
    Aliment Pharmacol Ther. 2023;58:141-142.
    >> Share

  418. ESTEVINHO MM, Magro F
    Editorial: elderly onset inflammatory bowel disease - clues from the largest population-based cohort study.
    Aliment Pharmacol Ther. 2023;58:116-117.
    >> Share

  419. HUDSON AS, Huynh HQ
    Editorial: Predicting paediatric ulcerative colitis outcomes-how can we improve?
    Aliment Pharmacol Ther. 2023;58:258-259.
    >> Share

  420. OH SJ, Kim HJ, Lee CK
    Editorial: Antibiotics and risk of IBD-Can we close the books? Authors' reply.
    Aliment Pharmacol Ther. 2023;58:256-257.
    >> Share

  421. EBRAHIMI F, Forss A
    Editorial: Antibiotics and risk of IBD-Can we close the books?
    Aliment Pharmacol Ther. 2023;58:254-255.
    >> Share

  422. BACSUR P, Ilias A, Resal T, Kata D, et al
    Letter: Experience of switching vedolizumab treatment from intravenous to subcutaneous formulation in Hungary.
    Aliment Pharmacol Ther. 2023;58:262-263.
    >> Share

    June 2023
  423. D'HAENS G, Peyrin-Biroulet L, Marks DJB, Lisi E, et al
    A randomised, double-blind, placebo-controlled study of the LAG-3-depleting monoclonal antibody GSK2831781 in patients with active ulcerative colitis.
    Aliment Pharmacol Ther. 2023 Jun 16. doi: 10.1111/apt.17557.
    >> Share

  424. BOKEMEYER B, Plachta-Danielzik S, di Giuseppe R, Efken P, et al
    Real-world effectiveness of vedolizumab compared to anti-TNF agents in biologic-naive patients with ulcerative colitis: A two-year propensity-score-adjusted analysis from the prospective, observational VEDO(IBD) -study.
    Aliment Pharmacol Ther. 2023 Jun 15. doi: 10.1111/apt.17616.
    >> Share

  425. NGUYEN AL, Burns M, Herath M, Lambell K, et al
    Accuracy of ultrasound, bioelectrical impedance analysis and anthropometry as point-of-care measurements of skeletal muscle mass in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023 Jun 12. doi: 10.1111/apt.17607.
    >> Share

  426. KOCHHAR GS, Desai A, Farraye FA, Cross RK, et al
    Efficacy of biologic and small molecule agents as second-line therapy after exposure to TNF inhibitors in patients with ulcerative colitis: A propensity-matched cohort study.
    Aliment Pharmacol Ther. 2023 Jun 9. doi: 10.1111/apt.17570.
    >> Share

  427. MACALUSO FS, Orlando A
    Editorial: adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease-time for universal recommendation?
    Aliment Pharmacol Ther. 2023;57:1343-1344.
    >> Share

  428. CALDERA F, Spaulding AC, Hayney MS, Farraye FA, et al
    Editorial: adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease-time for universal recommendation? Authors' reply.
    Aliment Pharmacol Ther. 2023;57:1345-1346.
    >> Share

  429. CHEN P, Chen F
    Letter: 1-kestose, the smallest fructooligosaccharide component, protection for mild to moderate ulcerative colitis patients.
    Aliment Pharmacol Ther. 2023;57:1349-1350.
    >> Share

  430. IKEGAMI S, Nakamura M, Honda T, Kawashima H, et al
    Letter: 1-kestose, the smallest fructooligosaccharide component, protection for mild to moderate ulcerative colitis patients-authors' reply.
    Aliment Pharmacol Ther. 2023;57:1351-1352.
    >> Share

  431. HANZEL J, Drobne D
    Editorial: golimumab dosing intensification effective in ulcerative colitis with no need for therapeutic drug monitoring.
    Aliment Pharmacol Ther. 2023;57:1469-1470.
    >> Share

  432. SETHI S, Kumar A, Dias S, Blackwell J, et al
    Editorial: proactive anti-TNF drug monitoring in IBD-Ready for the prime time? Authors' reply.
    Aliment Pharmacol Ther. 2023;57:1455-1456.
    >> Share

  433. FUMERY M, Roblin X
    Editorial: golimumab dosing intensification effective in ulcerative colitis with no need for therapeutic drug monitoring-author's reply.
    Aliment Pharmacol Ther. 2023;57:1471-1472.
    >> Share

  434. ROBLIN X, Nancey S
    Editorial: proactive anti-TNF drug monitoring in IBD-Ready for prime time?
    Aliment Pharmacol Ther. 2023;57:1453-1454.
    >> Share

  435. POLLOK RC, Jayasooriya N, Baillie S, Blackwell J, et al
    Letter: delays to diagnosis of IBD-Challenges requiring a systematic approach. Authors' reply.
    Aliment Pharmacol Ther. 2023;57:1479.
    >> Share

  436. CHANG HC, Gau SY
    Letter: histologic disease activity and colorectal neoplasia risk.
    Aliment Pharmacol Ther. 2023;57:1480.
    >> Share

  437. LUCAS S, Chauhan A, Garg M
    Letter: delays to diagnosis of IBD-Challenges requiring a systematic approach.
    Aliment Pharmacol Ther. 2023;57:1477-1478.
    >> Share

    May 2023
  438. ATIA O, Klomberg RCW, de Ridder L, Kemos P, et al
    Validation of predictive models for disease outcomes in paediatric ulcerative colitis: A multicentre prospective inception cohort.
    Aliment Pharmacol Ther. 2023 May 29. doi: 10.1111/apt.17544.
    >> Share

  439. KREIJNE JE, Goetgebuer RL, Erler NS, De Boer NK, et al
    Cumulative exposure to immunomodulators increases risk of cervical neoplasia in women with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023 May 23. doi: 10.1111/apt.17555.
    >> Share

  440. YANAI H, Salomon N, Lahat A, Ungar B, et al
    Real-world experience with Curcumin-QingDai combination for patients with active ulcerative colitis: A retrospective multicentre cohort study.
    Aliment Pharmacol Ther. 2023 May 8. doi: 10.1111/apt.17538.
    >> Share

  441. OH SJ, Kim HJ, Lee CK
    A dose-dependent increase in the risk of inflammatory bowel disease after exposure to broad-spectrum antibiotics: A national population study in Korea.
    Aliment Pharmacol Ther. 2023 May 8. doi: 10.1111/apt.17542.
    >> Share

  442. CHEN J, Ruan X, Yuan S, Theodoratou E, et al
    Editorial: in search of environmental risk factors of Crohn's disease and ulcerative colitis with mendelian randomisation-authors' reply.
    Aliment Pharmacol Ther. 2023;57:1034-1035.
    >> Share

  443. VAN RULER O, Arkenbosch JHC, van der Woude CJ
    Editorial: Heal thyself-Autologous therapy for perianal Crohn's disease. Authors' reply.
    Aliment Pharmacol Ther. 2023;57:1030-1031.
    >> Share

  444. BURISCH J
    Editorial: Why are patients with Crohn's disease still treated with 5-aminosalicylates?
    Aliment Pharmacol Ther. 2023;57:1044-1045.
    >> Share

  445. DART RJ
    Editorial: Heal thyself-Autologous therapy for perianal Crohn's disease.
    Aliment Pharmacol Ther. 2023;57:1028-1029.
    >> Share

  446. MEYER A, Amiot A, Carbonnel F
    Editorial: in search of environmental risk factors of Crohn's disease and ulcerative colitis with mendelian randomisation.
    Aliment Pharmacol Ther. 2023;57:1032-1033.
    >> Share

  447. CHEN J, Ruan X, Yuan S, Theodoratou E, et al
    Letter: disentangling the role of redox-active compounds in the development of inflammatory bowel diseases-moving towards causal associations. Authors' reply.
    Aliment Pharmacol Ther. 2023;57:1048-1049.
    >> Share

  448. GEERTSEMA S, van Goor H, Dijkstra G, Faber KN, et al
    Letter: disentangling the role of redox-active compounds in the development of inflammatory bowel diseases - moving towards causal associations.
    Aliment Pharmacol Ther. 2023;57:1046-1047.
    >> Share

  449. SONNENBERG A, Genta RM
    Editorial: concurrence of coeliac disease with inflammatory bowel disease - is big data the final arbiter? Authors' reply.
    Aliment Pharmacol Ther. 2023;57:1155-1156.
    >> Share

  450. SZIGETI R, Krishna M, Kellermayer R
    Letter: fulminant-onset complicated inflammatory bowel disease (IBD)-a unique subtype?
    Aliment Pharmacol Ther. 2023;57:1192-1193.
    >> Share

  451. POLLOK RC, Baillie S, Jayasooriya N, Blackwell J, et al
    Letter: diagnostic delay in inflammatory bowel disease-Authors' reply.
    Aliment Pharmacol Ther. 2023;57:1205-1206.
    >> Share

  452. ATIA O, Goren I, Yanai H
    Letter: 5-aminosalicylate maintenance treatment in mild Crohn's disease-authors' reply.
    Aliment Pharmacol Ther. 2023;57:1184-1185.
    >> Share

  453. ANDERSON RP
    Editorial: concurrence of coeliac disease with inflammatory bowel disease - is big data the final arbiter?
    Aliment Pharmacol Ther. 2023;57:1153-1154.
    >> Share

  454. TASSONE D, Gilmore R, Lee T, Ding NS, et al
    Letter: diagnostic delay in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023;57:1203-1204.
    >> Share

  455. JAYASOORIYA N, Saxena S, Pollok RC
    Letter: fulminant onset complicated inflammatory bowel disease (IBD) - a unique subtype? Authors' reply.
    Aliment Pharmacol Ther. 2023;57:1194-1195.
    >> Share

  456. CHANG HC, Gau SY
    Letter: 5-aminosalicylate maintenance treatment in mild Crohn's disease.
    Aliment Pharmacol Ther. 2023;57:1183.
    >> Share

    April 2023
  457. CASANOVA MJ, Nantes O, Varela P, Vela-Gonzalez M, et al
    Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA-SWITCH study.
    Aliment Pharmacol Ther. 2023 Apr 23. doi: 10.1111/apt.17525.
    >> Share

  458. NORGARD BM, Zegers FD, Knudsen T, Kjeldsen J, et al
    Patients with elderly onset inflammatory bowel disease have a decreased chance of initiation of all types of medications and increased risk of surgeries-A nationwide cohort study.
    Aliment Pharmacol Ther. 2023 Apr 20. doi: 10.1111/apt.17520.
    >> Share

  459. BOKEMEYER B, Plachta-Danielzik S, di Giuseppe R, Helwig U, et al
    Evaluation of a downstaging, bidirectional version of the Montreal classification of Crohn's disease: Analysis of 5-year follow-up data from the prospective BioCrohn study.
    Aliment Pharmacol Ther. 2023 Apr 13. doi: 10.1111/apt.17512.
    >> Share

  460. GOLD SL, Raman M, Sands BE, Ungaro R, et al
    Review article: Putting some muscle into sarcopenia-the pathogenesis, assessment and clinical impact of muscle loss in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023 Apr 13. doi: 10.1111/apt.17498.
    >> Share

  461. OLIVERA PA, Lasa JS, Peretto G, Zuily S, et al
    Review article: Risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugs.
    Aliment Pharmacol Ther. 2023 Apr 10. doi: 10.1111/apt.17509.
    >> Share

  462. VASANT DH, Nigam GB, Bate S, Hamdy S, et al
    The prevalence and burden of Rome IV faecal incontinence in ulcerative colitis: A cross-sectional study.
    Aliment Pharmacol Ther. 2023 Apr 3. doi: 10.1111/apt.17502.
    >> Share

  463. GUPTA A, Kedia S, Ahuja V
    Letter: trial of antitubercular therapy for diagnosing Crohn's disease in LMICs-double whammy?
    Aliment Pharmacol Ther. 2023;57:815-816.
    >> Share

  464. SPEEDY AP, Wall CL
    Editorial: Interdisciplinary and multidisciplinary approach to malnutrition in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023;57:907-908.
    >> Share

    March 2023
  465. WOLF T, Lewis A, Beaugerie L, Svrcek M, et al
    Risk of colorectal neoplasia according to histologic disease activity in patients with inflammatory bowel disease and colonic post-inflammatory polyps.
    Aliment Pharmacol Ther. 2023 Mar 31. doi: 10.1111/apt.17495.
    >> Share

  466. CALDERA F, Spaulding AC, Borah B, Moriarty J, et al
    Cost-effectiveness of an adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023 Mar 10. doi: 10.1111/apt.17454.
    >> Share

  467. ATIA O, Goren I, Fischler TS, Weisband YL, et al
    5-aminosalicylate maintenance is not superior to no maintenance in patients with newly diagnosed Crohn's disease-A nationwide cohort study.
    Aliment Pharmacol Ther. 2023 Mar 9. doi: 10.1111/apt.17419.
    >> Share

  468. MELTON SL, Taylor KM, Gibson PR, Halmos EP, et al
    Review article: Mechanisms underlying the effectiveness of exclusive enteral nutrition in Crohn's disease.
    Aliment Pharmacol Ther. 2023 Mar 9. doi: 10.1111/apt.17451.
    >> Share

    February 2023
  469. FUMERY M, Nancey S, Filippi J, Altwegg R, et al
    Effectiveness of golimumab intensification in ulcerative colitis: A multicentric prospective study.
    Aliment Pharmacol Ther. 2023 Feb 27. doi: 10.1111/apt.17421.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016